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Resumo 
 
Affibodies (ZZ) são pequenas proteínas de afinidade que podem ser modificadas 
para se ligarem a alvos específicos. Estas proteínas têm sido sugeridas como uma 
alternativa a anticorpos, devido ao seu processo de produção mais simples e 
barato. Assim, o objetivo deste trabalho de mestrado visou a possibilidade da 
utilização de um affibody (ZZapo) para a captura da Apolipoproteina-A1 (Apo-
A1) e sua deteção com anticorpos Anti-Apo-A1 conjugados com Nanopartículas 
de Ouro (AuNPs) num Dispositivo Microfluídico Analítico de Papel (µPAD). 
Para atingir o objetivo proposto, a fusão de uma molécula com afinidade a 
carboidratos da família 64 (CBM64) com o affibody ZZapo (ZZapo-CBM64) foi 
desenhada, produzida em E.coli, sequenciada, purificada e quantificada com 
sucesso. A fusão ZZapo-CBM64 foi comparada com a fusão semelhante ZZ-
CBM64, que tem afinidade para imunoglobulina G (IgG). Foi testada a 
capacidade de ligação das fusões à celulose, tendo-se verificado que ambas 
apresentaram alta afinidade a micropartículas e papel de celulose. Foi ainda 
testada a capacidade de ligação das duas fusões a IgG, pela utilização de IgG 
marcado com fluorescência. No entanto, ao contrário da ZZ-CBM64, a ZZapo-
CBM64 não mostrou afinidade para a IgG. Um teste µPAD foi criado com 
barreiras impressas a cera hidrofóbica, e com um adesivo na base do teste, o que 
permitiu os testes serem feitos em superfícies planas e ainda contribuiu para um 
fluxo da amostra mais rápido. Os testes µPAD mostraram interações não 
específicas entre ZZapo-CBM64 e AuNPs, que foram removidas pela conjugação 
das AuNPs com Albumina de Soro Bovino (BSA) e adição de BSA e Tween20 
à solução tampão. Os testes µPAD para deteção da Apo-A1 mostraram 
interações não específicas entre Apo-A1 e a membrana adesiva, que foram 
removidas pela utilização de um tampão de Bicarbonato de Amónia com BSA e 
Tween20. A deteção de Apo-A1 em µPADs não foi conseguida devido ao 
ZZapo-CBM64 não capturar a Apo-A1. Esta falha poderá ser devido a algum 
bloqueio da zona de captura relacionado com a estrutura 3D da fusão. De modo 
a ultrapassar esta questão, deverão ser realizados trabalhos futuros para o estudo 
da estrutura 3D da fusão, assim como estudo de outras fusões com diferentes 
variantes de affibodies para averiguar se o problema é exclusivo à fusão ZZapo-
CBM64 ou não. 
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Abstract Affibodies (ZZ) are small affinity proteins that can be engineered to bind to 
specific targets. These molecules have emerged as an alternative to antibodies 
due to their simpler and cheaper production process. The objective of this work 
was thus to assess the possibility of using an affibody (ZZapo) to capture 
Apolipoprotein-A1 (Apo-A1) and its detection using Anti-Apo-A1 antibodies 
conjugated to Gold Nanoparticles (AuNPs) on a Microfluidic Paper-Based 
Analytical Device (µPAD). To achieve the proposed objective, a fusion of a 
Carbohydrate Binding Molecule of the family 64 (CBM64) with a ZZapo affibody 
(ZZapo-CBM64) was successfully designed, produced in E. coli, sequenced, 
purified and quantified. The ZZapo-CBM64 fusion was then compared to a similar 
ZZ-CBM64 fusion (produced and purified in the same way) with immunoglobulin 
G (IgG) binding capacity, and tested for its cellulose binding capacity. Both 
fusions showed high affinity to cellulose particles and paper. They were also 
tested for IgG binding capacity, using a fluorescently labelled IgG. While ZZ-
CBM64 successfully captured IgG, the new ZZapo-CBM64 did not capture the 
labelled IgG. A µPAD test was designed and produced with wax printed 
hydrophobic barriers, and the use of an adhesive membrane in the bottom of the 
test enabled running tests on a flat surface, and contributed for faster sample flow. 
µPAD tests showed that ZZapo-CBM64 and AuNPs had non-specific interactions, 
which were removed by conjugating AuNPs with Bovine Serum Albumin (BSA) 
and using a buffer containing BSA and Tween20. µPAD tests for the detection of 
Apo-A1 showed non-specific binding of Apo-A1 and the adhesive membrane, 
which was removed by using ammonium bicarbonate buffer. Apo-A1 detection 
in µPADs was unsuccessful, which was shown to be caused by ZZapo-CBM64 
failing to capture Apo-A1. This failed capture could be caused by the capture 
zone of the protein being blocked. Future works should be directed to the study 
of the 3D structure of this fusion, as well as the study of other fusions with 
different affibody variants to assess if this problem is exclusive to ZZapo-CBM64 
or not. 
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INTRODUCTION 
1 AFFIBODIES 
Antibodies are the most successful and widespread affinity protein used in biochemical 
applications. The preference of these molecules is due to the capacity of being isolated with 
high affinity and specificity to any given target, as well as being a well-documented 
technology and being readily available (1). These molecules, however, also present several 
limitations caused by their molecular structure, such as low heat stability and complex and 
expensive manufacturing processes. Although they are large molecules, only a small part of 
them is used for target recognition and the bulk of the antibody structure adds complexity 
when evaluating the molecules. As such, there has also been a large focus in the investigation 
of novel affinity molecules with simpler structures and high affinity and specificity, such as 
affibody molecules (2). 
Affibodies are small proteins (6 kDa), that are engineered to bind to specific proteins. 
Its scaffold structure is an engineered variant of the B domain (Fc-binding portion) of 
Staphylococcal protein A mutated at key positions for increased chemical stability, the Z-
domain (ZZ), which has high affinity to immunoglobulin G (IgG). They possess a three 
alpha-helix structure, containing 58 amino acids (3,4). Affibody production uses synthetic 
combinatorial libraries generated by randomizing 13 surface amino acids on helices one and 
two and using phage display technology, which are highly tolerable to random amino acid 
substitutions. These libraries are displayed on phages, following biopanning against different 
targets, creating affibody variants that recognize varied targets such as Taq polymerase, 
human insulin, human serum albumin and human apolipoprotein-A1 (Apo-A1) (2,4,5). This 
technology allows recombinant production of affibodies in bacteria, such as E.coli, making 
it cheaper and easier to produce than antibodies. Affibodies can also be produced by 
chemical peptide synthesis, due to their small size and rapid folding properties, making it 
possible to introduce functional groups of interest, such as reporting agents (6,7). Even with 
these extra functional groups, affibodies are still considerably smaller than an antibody. In a 
recent paper, Lindgren et al. (8) reported that solid-phase peptide synthesis of affibodies 
with fluorophores combines high-yield and purity with simple and fast preparation of 
different variants of affibodies (8,9). These molecules also present several advantages when 
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compared with antibodies. Because they are composed of alpha-helices, they do not have 
disulphide bonds, which enables intracellular applications. They also have a spatially well-
defined surface area where amino acids can be modified, as explained previously, to create 
variants of interest, which have been proven useful to target various signal receptors and 
cancer-related molecules, such as the production of in vivo molecular probes (9). 
Affibody research has been largely focused on antigens for tumours, specifically with 
Human Epidermal Growth Factor Receptor 2 (HER2), which is used as an imaging agent in 
tumour imaging, a technique that is used to precisely localize primary tumours and 
metastatic lesions in a non-invasive fashion (9). Affibodies show great promise as imaging 
agents due to their small structure, resulting in rapid biodistribution and extravasation,  and 
are among the most investigated alternative binding proteins in imaging (2). Baum et al. (10) 
created the first affibody to be used in humans, namely for breast cancer imaging using 
HER2-binding affibodies.. Several authors have shown the use of labelled affibodies with 
radionuclides as imaging probes for Single-Photon Emission Computed Tomography 
(SPECT) and Position Emission Tomography (PET), such as 99mTc (metastable technetium-
99), 111In (indium), 68Ga (gallium) and 124I (iodine), finding that affibodies provided high 
contrast in imaging due to their affinity to HER2 (11–14). More recently, Sexton et al. (15) 
showed that fluorescently labelled HER2-binding affibodies performed better in tumour 
imaging than antibodies, due to their smaller size. Furthermore, Rosik et al. (16) reported 
that the biodistribution of these molecules could be improved by inserting a triglutamyl 
spacer after the radiofluorination with 18F-4-Fluorobenzaldehyde. They also noted that one 
hour after the injection of affibodies, only the kidneys and tumour were highly marked with 
radioactivity, however, two hours after the injection only the tumour was marked (16). Gao 
et al. (17) further proved that affibodies are good substitutes for antibodies when used as 
probes for cell and tumour imaging by conjugating maleimide-functionalized nanoparticles 
with affibodies that target HER2, verifying a strong signal in magnetic resonance imaging 
from cells that were incubated with the affibody-nanoparticle conjugates. Another study 
found that these conjugates have better targeting ability than radiolabelled affibodies, and 
are also better suited for in-vivo testing (18). More recently, another study showed the 
possibility of generating bispecific affibodies, capable of specifically capturing two targets. 
This experiment consisted in evaluating the effectiveness of bispecific affibodies, which 
have two binding domains for HER2 and HER3 to target tumours, and a third albumin 
3 
  
binding domain to provide longer in-vivo circulatory life. They found that these bispecific 
affibodies could bind to any of the three targets, and, in addition, showed an anti-proliferative 
effect due to inhibiting phosphorylation of HER receptors (7). In 2014, these HER2-binding 
affibodies were used to detect precursors to metastatic cancer, improving utility and cost 
effectiveness on HER2-targeted therapies (19,20). One of the most successful experiments 
in HER2-targeted therapies for radioimmunotherapy used radiometals attached to HER2-
binding affibodies fused with a small Albumin Binding Domain (ABD). They found that 
these ABD-fused affibodies had a significant reduction in kidney cells recognition, and 
delivered isothiocyanate (a cell apoptosis inducer) to the tumour when compared to the non-
ABD-fused affibodies, showing a great potential for tumour-targeted drug delivery (21). 
Besides imaging and diagnostics, affibody properties also allow them to be applied in 
several other fields of study, such as therapeutics, protein purification and bioassays, which 
we will be exploring further. Affibodies have already been shown useful in protein 
purification through affinity chromatography. By coupling to affibodies to chromatographic 
resins, affibody targets can be captured when a complex sample is run through a column 
packed with this affinity resin (22). Affibodies were shown to be an efficient replacement to 
antibodies in immunoaffinity chromatography due to their high specificity, performance and 
simple structure. In order to further investigate efficiency, Anderson et al. (23) compared 
purity and yield of a Human Serum Albumin (HSA) Sepharose column with an affibody-
targeted column in the separation of G protein from hamster kidney cells, and found that 
affibodies provided a much higher yield and purity. More recently, these molecules were 
used in affinity chromatography to recover other affibody variants with common HER2 
binding surface, which showed efficient capture with high specificity and sensitivity, thus 
further supporting the efficiency of affibodies in protein purification (22). 
Affibodies have also been applied in protein capture and detection and used as affinity 
probes in bioassays (20). Recently, anti-IgG affibodies conjugated with polystyrene 
nanobeads were shown to be more effective in the capacity to immobilize the fluorescently 
labelled IgG in comparison to microbeads, while also functioning as a sandwich assay to 
detect the amount of antibody with a very small sample (24). Andersson et al. (5) reported 
the use of affibodies in Enzyme-Linked Immunosorbent Assay (ELISA) as a way to remove 
false positives caused by Heterophilic Anti-Animal Ig Antibodies (HAIA) present in human 
serum in “sandwich” assays (Figure 1). HAIA can cross-link with capture and detection 
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antibodies creating false positives (25). The replacement of a capture or detection antibody 
with an affibody in these assays was reported to be an efficient way to remove HAIA 
interferences in ELISA as an alternative to other workarounds involving the use of more 
antibodies (5). 
 
Figure 1 - Common ELISA formats using a primary antibody coupled to an enzyme to yield a coloured product. Direct and 
indirect assays do not bind the analyte to a capture antibody, whereas capture assays do. Secondary conjugated antibodies 
are used in indirect assays. Adapted from (26). 
These studies show that affibodies are an emerging affinity molecule that could 
advantageously replace antibodies – they are cheaper and simpler to synthesize, their 
structure is less complex and can be used wide range of applications, especially in imaging, 
diagnostics and therapeutics. The incorporation of affibodies in bioassays and biosensors are 
not as well reported and should be further investigated due to their high specificity and 
affinity properties. As such, in this study, an affibody with binding affinity to Apo-A1 
(ZZapo), previously reported in literature (4), will be studied for its capacity of substituting 
Apo-A1 capture antibodies in a “sandwich” immunoassay. 
2 APOLIPOPROTEIN-A1 
Apo-A1 is the main component of High Density Lipoprotein (HDL), the “good” 
cholesterol. Apo-A1 constitutes about 70% of HDL content, defines its size and shape, and 
has a main role in lipid solubilization in HDL, cholesterol homeostasis and reverse 
cholesterol transportation (27). Its role in this transportation is due to Apo-A1 being a 
cofactor of Lecithin Cholesterol Acyl Transferase, which promotes the transport of 
cholesterol from tissues to the liver for excretion (28). This excretion is a contributing factor 
for atherosclerosis prevention, as it inhibits fat accumulation in white blood cells. This has 
been shown in a recent work (29) where Apo-A1 and HDL found in human atheroma 
(degenerative material found on artery walls) were oxidized and found to lose their ability 
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to excrete cholesterol, initiating the atherogenesis process, and increasing cardiovascular 
disease risk (30). 
Apo-A1 was also shown to have an important role in the inhibition of cognitive loss 
caused by Alzheimer’s disease. Apo-A1 can bind to Amyloid-β, a protein that is toxic to 
nerve cells causing cognitive deficit, attenuating its effects, and showing an anti-
inflammatory effect in the brain (31). Apo-A1 is mainly produced in the liver and intestine.  
However, it is still able to cross the blood-brain barrier and is present in cerebrospinal fluid 
and brain. Because of this, breaks in cholesterol homeostasis can be associated with 
Alzheimer’s disease (32).  
Anti-bacterial effects were also shown to be expressed by Apo-A1. Apo-A1 and 
antibacterial activity levels in serum highly increased when bacterial preparations were 
injected in mice, as well as showing toxin-neutralizing activity. Anti-viral activity is also 
expressed, although not totally understood, possibly by Apo-A1 being involved in viral 
inactivation, disrupting viral entry into the cell or inhibiting virus cell fusion (33). 
More recently, Apo-A1 was shown to have anti-tumour activity. Rather than directly 
inhibiting tumour cell growth, Apo-A1 affects the innate immune system by decreasing a 
tumour-permissive environment, reducing the expression of survivin, a protein that 
contributes to tumour proliferation by promoting cell-cycle activity. Apo-A1 also affects the 
adaptive immune system by inducing the expression of macrophages with anti-tumorigenic 
phenotypes (34). In addition, Lysophosphatidic Acid, which presents tumour proliferation 
activity, is cleared from serum by binding to Apo-A1, and this clearing activity is 
downregulated in ovarian, gastric and pancreatic cancer patients, indicating that Apo-A1 has 
an important role in clearing pro-inflammatory phospholipids like Lysophosphatidic Acid 
(35). 
These are just a few of the vastly reported immunomodulatory effects of Apo-A1 and 
HDL activity in biochemical processes of immunity, inflammation, viral and bacterial 
infection and tumour proliferation. However, there are not many reports of the use of the 
affibody ZZapo for Apo-A1 recognition. Further understanding the mechanisms Apo-A1 is 
involved in, as well as studying the advantages of using the ZZapo affibody for its capture 
could provide promising advances in Apo-A1 targeted therapeutics and diagnostics.  
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3 POINT-OF-CARE TESTING 
Molecular diagnostics focuses on the diagnosis of pathologies through biomarker 
detection or quantification. These biomarkers can be products of microbial or bacterial 
activity, viral RNA or enzymes and antibodies, but the most used biomarkers are proteins 
(36). Immunoassays, which use antibodies to capture a specific target, are the most popular 
choice for protein detection and quantification, they are well studied, can be used for a large 
number of antigens and are highly sensitive (1). However, these methods can result in slower 
diagnostics, may require experienced personnel and be costly due to the molecular 
components of these immunoassays. These are big disadvantages of this method, especially 
in resource limited settings (37). 
The World Health Organization suggests diagnostics in resource-limited settings should 
be ASSURED: Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-
free and Deliverable. This is where Point-of-Care (POC) testing becomes most relevant (38). 
POC testing has been defined as patient specimens assayed at or near the patient with the 
assumption that test results will be available instantly or in a very short timeframe to assist 
caregivers with immediate diagnosis and/or clinical intervention (39). POC testing has 
emerged as a solution to the problems associated with healthcare infrastructure in developing 
countries, such as lack of resources and qualified personnel. It has the potential of delivering 
diagnostic results rapidly, while also being simple, inexpensive, disposable and portable, 
which is very attractive in resource limited settings (40,41). According to the Food and Drug 
Administration (FDA), a simple test has to be user-friendly in a way that it should be easy 
to use and doesn’t require additional equipment or calculations/interpretation of the results 
to be read (detailed characteristics in Table 1). Some examples of currently available POC 
tests are blood glucose monitoring, pregnancy tests, arterial blood gas and HIV tests, which 
are all simple to conduct and for result interpretation (37). 
Microfluidic technologies are a rapidly advancing field with great relevance in POC 
testing, as they allow the development of solutions for sample processing, assay performance 
and analyte detection at small scales. They exploit the small size of channels to promote the 
movement of micro quantities of fluids (39,42). There are plenty of microfluidic devices 
available already today, which can be classified depending on their mode of operation. 
Dipstick, cartridge and lateral flow are the types that stand out. Dipstick tests consist of 
porous pads that contain reagents and use reflectance technology to give a semi-quantitative 
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estimate of the analyte, which can go up to ten tests at once. They can also be coupled with 
reading devices to reduce user error, or have several layers to separate the red cells of a blood 
sample (37). Cartridge tests consist of a cartridge and a signal reader. A sample of blood is 
placed in the cartridge which in turn is placed in a reader for measurement. This reader is 
different for each type of analyte to measure, for example a glucometer that measures 
glucose in blood. They utilize thin-film electrodes fabricated on silicon chips for the sample 
analysis. These chips have different electrodes for different analytes, for instance, urine tests 
measure the ammonium ions that are produced by the hydrolyzation of urea, whereas glucose 
tests measure hydrogen peroxide produced by the glucose oxidase reaction (43). 
Table 1 - FDAs’ definition of a simple diagnostic test. Adapted from Yager et.al. (44). 
FDA’s Definition of a Simple Test 
Fully automated instrument or unitized, self-contained test 
Uses direct unprocessed specimens/capillary blood (finger-stick), nasal swabs, or urine 
Needs only basic, non-technique-dependent specimen manipulation, including any for 
decontamination 
Needs only basic, non-technique-dependent reagent manipulation (“mix reagent A and 
reagent B”) 
Needs no operator intervention during the analysis steps, no technical or specialized training 
and no electronic or mechanical maintenance 
Produces results that require no operator calibration, interpretation, or calculations 
Produces results that are clear to read, such as positive or negative, a direct readout of 
numerical values, the clear presence or absence of a line, or obvious colour gradations 
Has test performance comparable to a traceable reference method, as demonstrated by 
studies in which intended operators perform the test 
Contains a quick reference instruction sheet written at the educational level of the user 
 
Lastly, Lateral Flow Assays (LFA), which will be the focus of this work, consists of a strip 
of material with recognition biomolecules (e.g antibodies) anchored on precise locations 
along which the liquid sample along with the target analyte moves. This provides qualitative 
and semi-quantitative results (45). Although the most common LFA nowadays are being 
used for the measurement of glucose and pregnancy tests, which measure human chorionic 
gonadotropin (hCG) in urine (hormone produced by the placenta after implantation of the 
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egg), there are tests available for drugs and infectious diseases that are also highly accurate 
(37,45). Notable examples include the detection of Citrus Tristeza virus infection in leaves 
or fruits (46), influenza (47), cocaine, ketamine, methadone, amongst others (48). One lateral 
flow technology that has received great attention lately, due to its simplicity and low cost, 
are the paper-based microfluidic devices, which will be elaborated on in the next section. 
Most traditional LFA are made of materials like glass, silicone or polymers such as 
poly(dimethylsiloxane) (PDMS) and poly(methylmethacryalate) (PMMA), which require 
specific complex fabrication processes and also some extra devices such as pumping systems 
to move the sample through the test (49,50). On the other hand, LFA can be made of paper, 
a material that is cheap, highly available and easy to manipulate. Paper devices can be mass 
produced at a very low cost, making it an ideal platform for POC devices, as well as making 
it an attractive matrix for bioassays.  
4 MICROFLUIDIC PAPER-BASED ANALYTICAL DEVICES 
Microfluidic Paper-based Analytical Devices (µPADs) are LFA conducted on paper 
matrixes using micro volumes of samples and reagents. They have received great attention 
in recent years due to their advantages in POC testing due to the use of paper (51). When 
compared to traditional materials, paper matrixes can be read visually, do not require pumps 
for the sample flow and are cheap and widely available (Table 2). 
Table 2 - Comparison of traditional and paper-based devices (52). 
 Traditional Paper-Based 
Material Manufacture 
Glass, Silicon, Polymers 
Channel Fabrication 
Surface Modification 
Paper 
Hydrophilic Channels (paper) 
Hydrophobic Channel Barriers 
Sample Driving Force Pump Capillary Force  
Result Analysis Reader Reader or Visual 
 
Paper fabrication is an important milestone in human history. However, and excluding 
the use of filter paper for pH determination, it wasn’t until 1949 that the first reports of paper-
based microfluidic devices appeared in the works of Muller and Clegg (53). These authors 
used a filter paper with a wax barrier and observed that the restriction of the sample sped up 
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its diffusion by capillarity on the paper. The first demonstration of paper-based microfluidics 
was made by Whitesides et al. in 2007 (54) for the fabrication of µPADs, and was 
highlighted as an emerging technology in 2009. 
The two main types of materials utilized for the fabrication of Paper-Based Devices 
are cellulose fibres, such as filter and chromatography paper, and nitrocellulose membranes. 
The ones used for µPADs are cellulose fibres, whereas nitrocellulose, which is naturally 
hydrophobic and requires deposition of surfactants, is commonly used in dipsticks and other 
LFA, such as pregnancy tests (55,56). Paper has many advantages when compared to other 
materials, the most obvious ones being its wide availability, it’s inexpensive, even for high-
quality chromatography paper, easily disposable and biodegradable (57). It’s also a great 
platform for diagnostics as cellulose is exceptionally biocompatible, it is a good filter, its 
porous structures facilitate lateral-flow assays without the need of pumps for sample flow 
and it can be covalently bound to proteins and other biomolecules. The fact that it is white 
is also a great advantage because it makes it a good medium for colorimetric tests (58), being 
the material of choice for this work. 
The process of manufacturing µPADs consists of physical or chemical patterning of 
hydrophobic barriers onto sheets of hydrophilic paper, making hydrophilic channels that 
contain the sample which can be open or sealed (59). Table 3 contains a summary of the 
most common patterning techniques used in the fabrication of µPADs along with some 
advantages and disadvantages. These hydrophilic channels patterning techniques used in the 
fabrication of µPADs along with their advantages and disadvantages. Most techniques use 
physical methods for patterning the paper, except for plasma etching and Alkyl Ketene 
Dimer (AKD) printing. Most of the methods require some specific equipment for the 
patterning (usually specific printers), which can be a disadvantage. However, wax printing 
has further advantages of simple and fast fabrication while also being easily replicated for 
mass fabrication and having good resolution (57,59). 
Table 3 - Main methods of µPAD barrier patterning and their advantages and disadvantages. Adapted from (57,59) 
 Method Material Advantages Disadvantages 
Physical 
Deposition 
Photolithography Photoresist Good Resolution Expensive Equipment 
Plotting PDMS Cheap/Flexible Needs Customized Plotter 
Ink Jet Etching Polystyrene Good Resolution Needs Customized Printer 
Screen Printing Wax Simple Low Resolution 
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Wax Printing Wax Simple and Fast Needs Wax Printer 
Laser Treatment Silicone/Wax High Resolution Does not allow LFA 
Flexography Polystyrene No heat treatment Needs several layers 
Chemical 
Deposition 
Plasma Etching AKD Cheap Needs Custom Molds 
AKD Printing AKD Simple and Fast Custom Printer 
  In recent years, there has been an increased interest in the development of different 
µPAD fabrication methods, which focus different strategies, such as using different barrier 
materials for increased solvent compatibility, various designs for flow control, and new 
porous materials for more resistance against aggressive reagents (60). A paper highlighted 
the use of pullulan as an alternative barrier material to the typically used ones (Table 3). This 
polysaccharide polymer was combined with wax to create omniphobic µPADs resistant to 
organic solvents (61).  Xu et al.(62) shows that hydrophobic barriers can be patterned with 
materials as simple as Sharpie (permanent maker) ink, which was loaded into cartridges for 
ink jet printing. One of the components of theses inks, however, is ethanol, which evaporates 
and results in low shelf life. Hand drawn barriers were also demonstrated, due to their 
simplicity and portability. A group showed the possibility of combining biologically relevant 
reagents with graphite pressed into pellets to be used in mechanical pencils, which produced 
a longer lasting signal than the same signal in solution form (63). Another author highlighted 
the use of ink pens to create hand drawn hydrophobic barriers, by using a trichloro 
perfluoroalkyl silane in hexanes ink, since the trichloro silanes react with paper to create 
hydrophobic barriers. The latter µPADs showed great versatility and great performance in 
colorimetric and ELISA tests (64). However, since the objective of this work is to create a 
simple µPAD, the method of choice will simply be wax printing, since the necessary 
equipment is available and it’s a simple and quick methodology for designing and producing 
the tests, it’s easily adjusted and reproduced and has great potential for mass production. 
4.1  WAX PRINTING 
Wax printing can be used for most µPAD applications, and is best suited for 
production in large numbers. Its cost is estimated to be about 0.001$ per test, when using 
high quality chromatography paper (Whatman paper) (65). This paper is mostly used as it is 
hydrophilic, homogenous, pure, reproducible, biocompatible, available and inexpensive 
(57,65).  
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Figure 2 - Schematic representation of the three-step process of Wax Printed µPAD fabrication. 
 
The process for µPAD fabrication consists of three steps: the channel design, wax printing 
of the channels, and melting the wax (Figure 2). First, the design of the channel is made 
using appropriate software, such as the AutoCad program. It is then replicated in a single 
sheet of paper and printed in a wax printer. If a wax printer is not available, wax dipping can 
also be used, which consists in using a plate or oven and molten beeswax to design the 
channels with an iron mold. However this technique presents the disadvantages of uneven 
penetration of the paper matrix and requires more control of wax melting temperature and 
time (66). Once printed, the paper is then heated on a plate or oven at 150ºC to melt the wax 
and allow it to diffuse through the thickness of the paper. As it is observable on Figure 2, the 
wax not only melts through the paper, but it also spreads laterally. This must be taken into 
account when designing the channels (65,67). Carrilho et. al (65) proposed an equation based 
on Washburn’s equation to calculate this spreading: 
𝐿 = (
𝛾𝐷𝑡
4𝜂
)
1
2⁄
 
In this equation, L is the distance where a liquid of viscosity η and surface tension γ 
penetrates a porous material with average pore diameter D in time t. From this, the width of 
the melted barrier is given by the equation: 
𝑊𝐵 = 𝑊𝑃 + 2𝐿 
Where 𝑊𝐵 is the width of the barrier after melting and 𝑊𝑃 is the width of the printed barrier 
(65).  Even with its downsides, like low resolution of the devices, wax printing is still a fast, 
efficient and inexpensive method of fabrication that requires minimal knowledge to readily 
produce large amounts of µPADs with mostly elementary equipment (57,67). 
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4.2 SURFACE FUNCTIONALIZATION OF µPADS 
Surface functionalization of µPADs is the process of coating the device with specific 
molecules selected to interact with specific targets. This is what makes biological assays in 
µPADs possible (55,68). The paper is said to be bioactive when those specific molecules are 
coating it. Bioactive paper has several applications, one of which is LFA assays, where a 
sample is introduced in one end of the paper and capillary forces move the sample through 
the test areas (56). Attachment of the molecules to the paper is not a strict requirement, as 
dry paper can sorb aqueous solutions and keep non-volatile components after drying. 
However, this opens the possibility of buffers or samples washing away the adsorbed 
molecules, and there is no control over the distribution of the molecules. This is problematic 
when working with expensive biosensors such as antibodies, enzymes, aptamers and nucleic 
acids (56,69). In addition, immobilization techniques can significantly influence shelf-life 
of µPADs, especially when they are exposed to changes in temperature during storage and 
transportation. Nery et al. (70) conducted experiments in enzyme-based µPADs to assess the 
influence of different immobilization methods in their stability and performance, noting that 
enzymes encased in polymers were found to be more stable when compared with direct 
adsorption. Additionally, an immobilization method using bilayer ionic polymer mixed with 
enzymes resulted in a higher enzymatic activity (70). As such, immobilization methods can 
be further adapted to improve shelf life. 
 Immobilization is indeed an important step in paper functionalization, and there are 
four main methods of doing it (Table 4), physical, using natural forces between the cellulose 
and biosensor, chemical, where reagents are manipulated to form covalent bonds with 
cellulose, biochemical coupling, in which molecules with affinity to cellulose are bound to 
biosensors, and finally bioactive pigments, that couple colloidal particles with biosensors 
that are applied onto the paper (56). 
Table 4 - Main immobilization methods for paper functionalization and summary of their description (56) 
Immobilization Description 
Physical Biosensor adheres to the paper by van der Walls and electrostatic forces 
Chemical Covalent bonds fix the biosensor to the paper 
Biochemical Coupling Employs molecules that binds to paper and biorecognition molecules 
Bioactive Pigments Biosensors are coated on colloidal particles that are applied on the paper 
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Physical immobilization uses electrostatic and van der Walls forces to bind the 
biosensor molecules to the paper. However, since these forces are not very strong, the 
sensors are not strongly attached and can be washed away with washing buffers (56). For 
example, plasma proteins were shown to not strongly adsorb onto cellulose (71) and DNA 
with high molecular weight only adsorbs at pH 4 (72). Physical immobilization can be an 
easy method for some specific biosensor, however, it’s not a great method, as they are not 
strongly anchored to the cellulose and there is no control over biosensor orientation (73,74).  
Chemical immobilization uses covalent bonds to fix biosensors. Because pure 
cellulose doesn’t have many functional groups, one must manipulate it to form these groups, 
usually with a polymer or a small molecule, in order to make bioconjugation possible (75). 
One work highlights the oxidation of regenerated cellulose to form aldehyde groups that 
react with amine groups on a DNA aptamer to form a Schiff base and reducing it, forming a 
covalent bond (76). Other works have shown other processes for different biosensors, like 
antibodies and enzymes. One of the main drawbacks of this process is the multiple chemical 
steps involved in the process, which makes it more complex time consuming and expensive 
(77,78). 
Bioactive pigments consist in conjugating biosensors to colloidal particles, and then 
directly printing or spotting the whole structure onto the paper. It presents some advantages 
in comparison to other immobilization methods, such as the possibility of the complex 
coupling process being performed in specialized facilities and applied to the paper matrix 
later and to couple the colloidal particles with blocking and reporting functions (56,75). P(N-
isopropylacrylamide) (PNIPAM) is commonly used in this method, because it has low non-
specific protein binding (79). PNIPAM was also used in microgels coupled with DNA 
aptamers and antibodies, and stay immobilized on the paper matrix simply after spotting and 
letting it airdry (74). This method, however, does not allow correct orientation of the 
biosensors in the paper matrix, which could result in poor sensitivities and uneven visual 
signals (56). 
4.2.1 Biochemical Coupling 
The biochemical coupling method requires an intermediate molecule that binds the 
biorecognition molecule to the paper, which are applied directly to the test matrix by directly 
spotting the conjugate solution. The most commonly used ones in µPADs are the 
Carbohydrate Binding Molecules (CBMs), which have a high affinity to cellulose (75). 
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CBMs are defined as contiguous amino acid sequence within a carbohydrate-active enzyme 
with a discrete fold having carbohydrate binding activity. They are made up from 30 to 200 
amino acids and can be a single, double or triple domain in one protein and can be found in 
either terminal of the polypeptide chain and sometimes in the centre. CBMs from different 
proteins have been found to have similar structures and they bind to cellulose because of 
their hydrophobic surface composed of several aromatic amino acids (80). Using this type 
of immobilization, it is possible to correctly position the biomolecule on the paper surface, 
allowing for a correct distribution of colorimetric signals (69). There are already several 
works that show the possibility of fusing of these CBMs with proteins, forming complexes 
that allow the specific immobilization of antibodies (81), proteins (82) and bacteriophages 
(83) onto a cellulose matrix. The fusion of CBMs with the Z-domain (previously mentioned 
in section 1) has already been shown as a good medium for immunoassays in µPADs with 
wax printed channels (69). Furthermore, this affibody-CBM conjugate can be produced from 
E. coli, reducing production costs by substituting an antibody with an affibody variant. For 
this reason, we will use this immobilization method in this work, using a fusion of a CBM 
with an Apo-A1 binding affibody as a capture conjugate for the capture immunoassay. 
Because immobilization methods alone do not provide quantitative or qualitative 
information, an appropriate detection system must be chosen to assess assay results. 
4.3 DETECTION SYSTEMS 
The detection or quantification of the analyte is a critical step for µPADs, as they are 
used for analytical purposes. Depending on what kind of molecule one is trying to detect, 
one must appropriately choose a detection system. There is a wide array of detection 
mechanisms that have been proposed for µPADs. The most well-established techniques are 
colorimetry, electrochemical detection  and nanoparticle-based detection (52,84). Mass 
spectrometry, magneto-resistive sensors and nuclear magnetic resonance have also been 
applied in micro total analysis systems, however these are not as relevant for µPADs, as they 
employ expensive equipment (51).  
Colorimetry is the most commonly used method for detection, as it is simple and 
cheap. This technique consists in using molecular or enzymatic dyes in the sample to react 
with previously immobilized reagents. These reagents can be enzymes, acid-base indicators 
or dyes (84). When a sample contacts a reaction zone, it results in a colour change that can 
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determine analyte levels using a calibration chart, which makes this method semi-
quantitative. It also has the potential for multiplexing, which means, multiple reaction zones 
can be spotted in a single test (55). One paper highlights an excellent use of multiplexing for 
a titration of Ca2+ and Mg2+ in µPADs, as represented in Figure 3-A. It uses a single sample 
zone connected to ten reaction and detection zones with different concentrations of a 
chelating agent and a constant concentration of a metal indicator for colorimetric 
quantification (85). A distance-based multiplexed device was created to detect Ni, Fe and 
Cu in welding fumes. A ruler was printed onto the paper matrix to allow colour region length 
to be measured and quantified, allowing quick detection and quantification on site, which is 
represented in Figure 3-B (86). This methodology, however, presents a few disadvantages 
that are more evident when using micro volumes of reagents. Besides the small amount of 
sample used, buffers used in µPADs can wash away signalling components, which cause the 
signal colour to be spread unevenly and judgement of the colour can be challenging to the 
naked eye. This effect is not a problem for commercially available dipsticks, as there is a 
large amount of sample available (87). It can be time sensitive, since usually the colour of 
the dyes is only visible for a certain period of time before they become unreliable, and the 
results have to be read within that time window. Other dyes require some time to develop 
colour as well (37,55). Also, when a whole blood sample is used, red blood cells can make 
colorimetric reads difficult. However, spotting agglutination antibodies onto the µPAD 
before introducing the sample causes red blood cells to form aggregates too big to pass 
through the pores of the chromatography paper, while allowing blood plasma to sink into 
the paper (88). Furthermore, several layers of cellulose paper can act as a red blood cell filter 
(58). 
Electrochemical detection uses electrochemical sensors printed onto the paper matrix 
in contact with the reaction zones, which, when a reaction occurs, send signals captured by 
electrodes that are converted in numerical values by a reader (52, 55,89). The sensors are 
made of three main electrodes, a counter electrode, a working electrode and one or more 
reference electrodes. These are printed on the paper matrix, typically with carbon inks for 
the counter and working electrodes, and with silver for the reference electrodes (55, 84,90). 
These devices have been shown to work for several analytes, such as lactate, uric acid (91), 
glucose (90), tumour markers (89), amongst others (58).  
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Figure 3 – Representation of two µPADs with colorimetric detection: (A) Titration of 30 mM of Ca2+ and 30mM of Mg2+ 
at pH 13, using solutions of Ethylenediaminetetraacetic acid from 0-90mM on the reaction zones, represented by the 
numbers next to the reaction zones. The colour of the zones is represented by the letters P (Purple) and B (Blue). The 
concentration of the analytes is determined in the zone where the is no colour change (30mM in this image) (85). (B) 
Distance-based measurement for Ni, Fe and Cu over a period of 45 minutes. Colorimetric reagents and buffers are printed 
onto the detection and pre-treatment zones, as well as a colorimetric indicator printed on the back of the device. The analytes 
were quantified when a metal-ligand complex precipitated on the substrate which generated a band of colour with length 
proportional to the amount of metal present. When the reaction ends, the coloured zones are measured with the printed 
rulers next to the detection zones for determination of concentration (86). 
Since the concept of electrochemical detection is well known, it has become an attractive 
detection method for µPADs. It also has fast sensor responses and higher sensitivities. 
Furthermore, since they do not use colorimetric detection, they are not prone to incorrect 
visual reads and don’t require removal of red blood cells. (55,91). More recently, there has 
been great interest in novel patterning and electrode materials, as well as modifying 
electrodes, for lower cost, greater sensitivities and better recognition (60). Metal 
nanoparticles have been shown to improve stability and conductivity and have already been 
incorporated in the fabrication of electrodes. This method, however can involve expensive 
fabrication equipment, which presents a disadvantage (92). Additionally, enzymes can also 
be used in electrochemical detection, but must be immobilized into cellulose adjacent to 
electrodes, as if they are on electrodes, they may impede electron transfer (93). While 
electrochemical detection is analytically superior to colorimetric detection, it is attributed to 
the use of signal detectors, which increase complexity and costs. Furthermore, the use of 
electrodes results in additional production steps and costs when compared to colorimetry 
(58). While hand-drawing electrodes is a possibility, they have limited reproducibility and 
are not suited for mass production. Nevertheless, they present a versatile tool for making 
well performing ePADs (94). 
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4.3.1 Nanoparticle-based Detection 
Nanoparticles have already been shown to have great widespread use in cellulose and 
nitrocellulose-based paper platforms. While they can be used to improve electrochemical 
detection, they are generally used as a colorimetric method. They are attractive for detection 
purposes due to having higher stability and extinction coefficients than of common organic 
dyes, which means the colour is more intense and can be reliable for a longer period of time 
(55,84). They are also more sensitive, have lower detection limits and do not require a reader 
(95). AuNPs and monodisperse latex nanoparticles are commonly used in LFA, although 
AuNPs are preferred as they have more colour intensity and are smaller in size, and thus can 
easily adsorb into the paper in high densities, they are also easy to functionalize and are 
biocompatible (52,95,96). They possess a property that can be exploited for colorimetric 
detection, the Localized Surface Plasmon Resonance (LSPR). This property consists in the 
oscillation of the electrons in the gold atoms when they are exposed to light, polarizing the 
AuNPs and increasing their extinction coefficient, causing an intense colour (97). The size 
of the nanoparticles is an important factor when addressing colour intensity and particle 
stability, as bigger particles tend to have more sensitivity, however if they are bigger than 
40 nm they are less stable. AuNPs smaller than 15 nm do not show an intense colour, and 
particles that are larger than 60-70 nm show self-aggregation if stored at 4ºC for several days 
(95). When the diameter increases, the LSPR shifts the colour to dark purple, this diameter 
increase can be caused by particle aggregation or by a controlled interaction, which can be 
exploited for colorimetric applications. This shift in colour has already been exploited to 
detect the bacteria Mycoplasma pneumonia (98) as well as prostate specific antigen and HIV-
1 capsid antigen p24 (99) and other analytes, from nucleic acids to other small molecules at 
very low limits of detection, such as picomolar concentrations for proteins (97). Detection 
of E. coli was also shown on µPADs, AuNPs were coupled to lipopolysaccharide binding 
proteins, used to capture in a solution, and then transferred to paper. The presence of bacteria 
in the solution caused nanoparticles to aggregate, shifting colour from red to blue, with 
enough sensitivity to be applied to samples without amplification steps (116). Other works 
have shown the use of AuNPs as a detection tool for various clinically relevant biomolecules, 
environmental contaminants (100) and immunoassays (101,102). Furthermore, the use of 
hydrophobic barriers, such as wax barriers, on µPADs allows the fine-tuning of capillary 
flow and increasing the binding time between the analyte and the recognition molecule (97). 
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Since binding AuNPs to antibodies for immunoassays is a simple process (69), they have 
good reproducibility, can be finely tuned with different sizes for better signals and present 
fast results, they present an excellent tool for the optimization of POC devices, and will be 
the detection method used for this work. 
5 CURRENT ADVANCES AND CHALLENGES 
 Throughout this introduction, several studies related to the development of µPAD 
technology were reported. Since these studies, several others have been conducted to further 
improve these devices. Because colorimetry is one of the most used detection systems in 
POC testing, it allows for the processing of data through smartphone technology. Using a 
smartphone camera, it is possible to measure colour intensity on a test and quickly analyse 
and display the signal (95,103). A few works already show the use of this methodology in 
LFA for the detection of drug abuse in saliva (48), quantification of vitamin D (104) and in 
µPADs (105). However, there are still problems related with ambient illumination that create 
fluctuations in the quality and reproducibility of smartphone captured images that need to be 
addressed. 
Because these devices are made of paper, they can be easily manipulated and folded 
into three-dimensional (3D) devices, which is very advantageous for multiplexing and for 
more complex test matrixes, which gives them another focal point of interest (60). A 3D 
ePAD was created by Wang et al. which could be folded and unfolded to open or close the 
reaction zone for glucose electrochemical detection (106). The samples were introduced in 
the reaction zone when the device was open, let incubate for 2 minutes for enzymatic reaction 
to occur, and then it was closed to make contact with the detection zone and inserted into a 
glucometer, as represented in Figure 4. It was also shown to be useful in flow control as the 
sample only interacts with the detection when the user desires (106). Another much simpler 
3D device was developed by Camplisson et al., which consisted in a double ply channel 
made of wax. This channel was fabricated simply by stacking two single ply channels with 
a toner on the wax barriers, and then passed through a laminator. These channels showed a 
significant increase in flow speed at both 100% and 35% relative humidity in comparison to 
single ply channels (107). 
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Figure 4 – Photograph of the 3D ePAD developed for glucose detection and quantification with the use of a glucometer. 
The blood sample is introduced in the reaction zone, where enzymes are stored, after 2 minutes of incubation, the device is 
closed, allowing the sample to make contact with the detection zone and producing a signal read by the glucometer (106). 
Many authors aim to perform proof-of-concept experiments to show that certain 
analytes can be detected and quantified through µPAD technology. In recent years 
methodologies have been developed to extend µPAD use to several areas, like diagnostics, 
biochemical analysis, environmental monitoring, forensics and food quality control (108–
111). A paper device was developed for simultaneous glucose and lactate testing in blood 
samples using enzyme-functionalized starch. These tests showed sensitivities in clinically 
relevant ranges, along with long shelf life at room temperature, proving that these assays do 
not require refrigeration (112). Another µPAD was developed to assess human male fertility 
using colorimetry. It exploits the use of diaphorase flavoprotein enzyme, present in healthy 
human sperm, to changing a reagent’s colour from yellow to purple (113). Several tests 
relevant to environmental control have also been developed, such as an easy colorimetric 
test for on-site analysis, that consisted in chromatography paper patterned with wax to report 
the presence of Ni2+, Cu2+ and Cr6+ in water samples, simply by dipping the device in the 
sample (114). 3D paper sensors for the detection of organophosphate and carbamate 
pesticides were also developed using acetylcholinesterase to convert indoxyl acetate into a 
blue-coloured product, which is inhibited in the presence of the pesticides (115).  
Many experiments are also conducted to further show the versatility of µPADs, such 
as using them as a separation method. A report shows the capability of doing electrophoresis 
on µPADs for macromolecule separation, using a high electric field over a short distance 
(116). The devices were made of folded paper into thin layers, which allowed introduction 
and recovery of the sample by unfolding and cutting the layers of interest. It separated 
proteins from bovine serum rapidly and at low voltages (116). 
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Even though µPAD technologies are very promising for clinical applications due to 
their versatility and fine-tuneability, there are still many obstacles that need to be addressed, 
mainly related to their real world, out-of-lab applications. Most of their shortcomings are 
attributed to automation and standardization processes, especially when it comes to 
deposition of reactive components, as well as costs related to the molecular components of 
the assays, mainly of antibodies which represent most of the cost of lateral flow 
immunoassay devices (55, 95,103). Further exploring the use of alternative binding 
molecules, such as affibodies, could greatly reduce the costs of production of these devices 
and bring a greater interest for their further research and development. 
6 OBJECTIVES 
The main objective of this work is to study the possibility of developing a µPAD for 
detection of Apo-A1. For this purpose, a capture immunoassay was conceptually designed 
that combines a bi-functional protein fusion for antigen capture and a labelled antibody for 
detection. The protein fusion combines an affibody with affinity towards Apo-A1 (ZZapo) 
with the C-terminal of a family 64 Carbohydrate Binding Molecule (CBM) from Spirochaeta 
Thermophile. The CBM64 part recognizes the cellulose fibrils in paper (117), whereas the 
ZZapo module is able to recognize Apo-A1 (4). An Anti-Apo A1 antibody labelled with 
AuNPs is used for detection. A schematic representation of the Apo-A1 sandwich detection 
envisaged is shown in Figure 5-A. The µPAD is created on paper by using wax printing to 
define channels and reaction zones with a given geometry (Figure 5-B). To perform the Apo 
A1 detection, the ZZapo-CBM64 fusion is first anchored in the test zone. Then a certain 
volume of a test solution is dispensed on the sample zone of the device. These test solutions 
should include the Apo-A1 target coupled to the Anti-Apo-A1 antibody labelled with 
AuNPs. After migration of the test solution through the channel, the capture of the Apo-A1 
antigen should be revealed by the accumulation of a red colour (from the AuNPs) over the 
test zone (Figure 5-B). 
The first objective of this thesis was thus to produce and purify the fusion protein 
ZZapo-CBM64 in E. coli. Then, the cellulose and IgG binding properties of the ZZapo-
CBM64 fusion will be tested and compared with the previously reported fusion ZZ-CBM64, 
which uses the base affibody scaffold (ZZ), previously discussed in section 1, that binds to 
IgG via their Fc region (69). The next step is to design and produce a µPAD test with test 
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and control zones, for nanoparticle-based colorimetric detection, to optimize its design and 
study the interactions of ZZapo-CBM64, with AuNPs conjugated with anti-Apo-A1 IgG and 
unconjugated AuNPs. The composition of the running buffer will also be optimized with the 
goal of minimizing non-specific interactions between the molecular components in the test. 
Then the capture assay will be conducted to test the capture and detection of Apo-A1, as 
illustrated in Figure 5. The test zone will contain the ZZapo-CBM64 fusion and the control 
zone a Goat Anti-Mouse IgG. The test should yield a qualitative result regarding the capture 
and detection of Apo-A1. On a positive test, the red colour in the test and control zones are 
a result of the accumulation of the conjugated AuNPs, which will be the result of a 
complexation of ZZapo-CBM64, Apo-A1 and conjugated AuNPs in the test zone, and the 
capture of the conjugated AuNPs by the Goat Anti-Mouse antibody, for the validation of the 
test. If this capture and detection is successfully achieved, we will optimize the assay for a 
clinically relevant test, if not, we will try to ascertain the reason why the test is not working. 
 
 
Figure 5 - Schematic representation of the envisioned sandwich assay of a positive capture µPAD test for the detection of 
Apolipoprotein-A1, using a channel with wax barriers, a ZZapo-CBM64 fusion in the test zone (t) and a Goat Anti-Mouse 
IgG in the control zone (c). A sample containing Apo-A1 and AuNP conjugated Anti-Apo-A1 antibodies is run through 
the channel of the µPAD test to form a ZZapo-CBM64/Apo-A1/Anti-Apo-A1 complex in the test zone (t), and a Goat Anti-
Mouse/Anti-Apo-A1 complex in the control zone (c). 
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7 MATERIALS AND METHODS 
7.1 ZZAPO-CBM64 PRODUCTION 
The recombinant protein ZZapo-CBM64, with specific binding capacity to 
Apolipoprotein-A1 (Apo-A1) which will be used as a model in this work, was cloned in a 
plasmid (pET21a; 5432 bp; Ampicillin resistance, Appendix A contains the final vector map) 
and produced in Escherichia coli by NZYTech. The protein fusion combines the N-terminus 
of a human Apo-A1 recognizing affibody (ZZapo) (4), a linker, the C-terminal of a family 
64 Carbohydrate Binding Molecule (CBM) of Spirochaeta thermophile and a hexa-histidine 
tag. The corresponding 642 bp-long DNA sequence, which is represented in Figure 6, was 
cloned in the pET21a vector using the NdeI/XhoI enzymes, yielding a plasmid with 6074 
bp. The sequence of the recombinant protein is represented on Figure 7.  
 
Figure 6 -  Gene sequence of ZZapo-CBM64 (Spirochaeta thermophila) (642 bp, GC%=48%) 
 
Figure 7 - Recombinant protein sequence of the final ZZapo-CBM64 fusion (Spirochaeta thermophila). The molecular 
weight of the protein is of 24463.19 Da, as estimated by the Compute pI/Mw tool of the ExPASy Bioinformatics Resource 
Portal (https://www.expasy.org/). 
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For the protein production, competent E. coli DE3 strain BL21 cells (Novagen) were 
incubated with 1μL of the cloned vector and left on ice for 30 minutes, after which the cells 
were transformed by heat shock in a water bath (HAAKE DC10) at 42°C for 1 minute 
followed by 2 minutes in ice. The cells were then suspended in 1mL of pre-prepared Luria-
Bertani (LB) broth from powder (Nzytech) for 1h at 37°C. Following this incubation, the 
cells were plated in a culture medium supplemented with ampicillin and left incubating 
overnight at 37°C. Liquid LB broth media was then prepared according to manufacturer’s 
instructions and then autoclaved for 10min at 121ºC. The next day, a 30mL medium was 
supplemented with 100µg/mL of ampicillin and inoculated with a transformed white cell 
colony from the plated culture medium and cultured overnight at 37ºC at 260rpm. Its optical 
density (OD) was measured after the incubation at 600nm (OD600nm) to determine the amount 
of culture needed to inoculate a 250mL medium and another 30mL medium, prepared in the 
same way, to an OD600nm of 0.1. The calculated volumes were used to inoculate the 30mL 
and 250mL media, again supplemented with 100µg/mL of ampicillin, and incubated for 
about 1h, until an OD600nm of 1 was achieved. Protein expression was then induced in the 
250mL medium with 200µL of Isopropyl β-D-1-thiogalactopyranoside (IPTG) 1M (Fisher 
Scientific, BPΔ 755-10) and incubated for 6h at 37ºC, 260rpm. After the incubation, the 
culture was centrifuged at 4770rpm at 4ºC for 40min (Serial RCB, rotor SLC 3000). The 
supernatant was discarded and the pellet was resuspended in 1mL Tris-saline Tween 20 
buffer (TST buffer: 50 mM Tris buffer, pH 7.6, 150 mM NaCl, 0.05% Tween 20). The cells 
were then sonicated on ice for mechanical cell disruption using Banollin-Sonoplus sonicator 
and a MS72 probe at 30W for 6min with 30s pulses and 30s intervals. The suspension was 
then centrifuged again at 8680rpm for 20min (Serial RCB, Sorval SS34), and the pellet was 
discarded. 
 The 30mL culture was used to create cell banks in vials of 200µL of glycerol 99% 
and 800µL of culture medium and stored at -80ºC, these were used at a later time to produce 
and sequence ZZapo-CBM64. Using a 5mL LB broth medium, prepared in the same way as 
the previous ones supplemented with 100µg/mL of ampicillin, a cell bank was used to 
inoculate the medium and left at 37ºC, for about 2h, after which its OD600nm was measured 
to calculate the volume needed to inoculate a pre-prepared medium of 250mL LB broth to 
an OD600nm of 0.1. The rest of the protocol was the same as the previous one.  
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7.2 SEQUENCING OF ZZAPO-CBM64  
To evaluate if the produced vector had the expected sequence as presented in the report 
provided by NZYTech (Figure 6), vector sequencing was conducted. A cell bank of ZZapo-
CBM64 was cultured in a 5mL autoclaved LB broth medium supplemented with 100µg/mL 
of ampicillin overnight at 37ºC, 260rpm. The next day, plasmid DNA purification was 
achieved using a NZYMiniprep Kit (NZYTech MB01001) according to manufacturer’s 
instructions. The resulting DNA pool was analysed in a NanoVue Plus spectrophotometer to 
ascertain its concentration and purity, which was 190ng/µL and Absorbance260/280=1.939; 
Absorbance260/230=2.065. 
To confirm the presence of the ZZapo-CBM64 sequence, two restriction enzymes that 
contained this sequence were selected for digestion of the plasmid, which were XhoI 
(Thermo Scientific) and XbaI (Promega). One sample of 500ng of the plasmid DNA was 
incubated with 2U XhoI, and another sample was incubated with both enzymes, at the same 
ratio, for 1h30 at 37ºC, with the “Buffer D” (Promega, pH7.9, 6mM TrisHCl, 6mM MgCl2, 
150mM NaCl, 1mM DTT) which was the common optimal buffer for both restriction 
enzymes. A 1% (w/v) agarose gel was then prepared in TAE buffer (40mM Tris, 20mM 
Acetic Acid, 1mM EDTA), the agarose (Fisher Scientific) was dissolved in the buffer, heated 
for 10 seconds at a time in a microwave and stirred until all the agarose was dissolved, poured 
into a mold and let cool until solid. Samples were mixed with a 6x loading buffer (40% 
sucrose (w/v), 0.25% Bromophenol Blue (w/v)) and loaded into the gel using a NZYDNA 
ladder III MW marker (NZYTech), which was run in TAE buffer at 100V for 1h. Gels were 
stained in an ethidium bromide solution (0.4µg/mL) and images were obtained with an Eagle 
Eye II gel documentation system (Stratagene) and processed in ImageLab.  
The plasmid sequence was copied to the program SnapGene and 150 base pairs (bp) 
were selected before and after the ZZapo-CBM64 sequence to look for primers, which were 
evaluated in the program Oligoanalyzer for quality and for likelihood of forming hairpins 
and dimers. Once the best primers were selected, the purified DNA was sent to Stabvida for 
sequencing. The provided sequence was then compared with the original ZZapo-CBM64 
sequence (Figure 6) for mismatches. 
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7.3 ZZAPO-CBM64 PURIFICATION AND QUANTIFICATION 
The fusion protein was purified by metal affinity chromatography with a Niquel 
Sepharose 6 Fast Flow column (HisTrap FF; GE Healthcare) in an ÄKTApurifier 10 system 
(GE Healthcare). The protocol used was according to manufacturer’s instructions. Two 
buffers were used in the process, Buffer A (10mM Imidazole, 50mM NaHEPES pH 7.5; 1M 
NaCl, 5mM CaCl2) and Buffer B (300mM Imidazole, 50mM NaHEPES pH 7.5; 1M NaCl, 
5mM CaCl2). The column was equilibrated with 5 column volumes of buffer A and the 
supernatant was loaded in the column. The unbound proteins were eluted with 20 volumes 
of buffer A and the ZZapo-CBM64 protein was eluted with 10 volumes of buffer B. 
To evaluate the purity of the purified protein, a Sodium Dodecyl Sulphate 
Polyacrylamide gel electrophoresis (SDS-PAGE) was performed. The polyacrylamide gels 
were synthesized with 12% acrylamide and bis-acrylamide total concentration and 3.3% of 
bis-acrylamide for the resolving gel, and 4% total concentration and 3.3% of bis-acrylamide 
for the stacking gel. The samples were prepared by adding 5μL of denaturing agent 1 M 
Dithiothreitol (DTT) (Sigma Aldrich), 25μL of 2x Laemmli Sample Buffer (Bio-Rad) 
prepared according to manufacturer’s instructions and 20μL of purified sample. The samples 
were incubated for 10 minutes in a 100°C water bath and were then placed in gel. A 10-
250kDa protein ladder (Bio-Rad, Precision Plus Protein Standards) was used as a molecular 
mass marker. The gel was run at 90V until the front of the gel reached the end of the gel 
plates. Coomassie Brilliant Blue was used to stain the gels and destaining was achieved with 
a 30% ethanol and 10% acetic acid solution. Images of SDS-PAGE gels were obtained with 
GS-800™ Calibrated Densitometer (Bio-Rad) and processed in ImageLab. 
Quantification of the ZZapo-CBM64 protein was achieved with the Bicinchoninic Acid 
(BCA) Protein Assay using the microplate procedure of Pierce® BCA Protein Assay kit 
(Thermo Scientific), prepared according to manufacturer’s instructions.  
7.4 COMPARISON OF ZZAPO-CBM64 WITH ZZ-CBM64 
To evaluate efficiency and properties of the novel ZZapo-CBM64, a few tests were 
conducted to compare it with a ZZ-CBM64 protein (previously synthesized by a colleague 
using a method similar to the production and purification section described above). In this 
second fusion, the ZZ portion has a strong affinity to the Fc portion of antibodies. 
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To assess if the new construct has similar binding properties to cellulose 3 samples of 
20pmol of both proteins were diluted to a final volume of 15µL using Phosphate Buffered 
Saline (PBS, 137mM NaCl, 10mM Phosphate, 2.7mM KCl, pH 7.4), and on the blank 
samples, 20µL of PBS was added. On the second set, 20µL of a 20µM micro-cellulose 
particles (Sigma-Aldrich Sigmacell Cellulose type 20 diluted in PBS) suspension was added 
and on the third set, a strip of Whatman no.1 chromatography paper was added (3mmx2mm) 
along with 20µL of PBS. These samples were incubated for 10min on a shaker (VWR Digital 
Vortex Mixer) at Room Temperature (RT) after which they were centrifuged at 2000g (VWR 
Ministar Silverline) for 5min and a 20µL sample of each test was submitted to SDS-PAGE 
(in the same conditions as described above). The gel was then stained with Silver Nitrate. 
First the gel was incubated on a shaker for 2h with a 30% ethanol and 10% acetic acid 
solution for fixation, followed by two washing steps, the first one with a 30% ethanol 
solution for 10min, and the second with MilliQ water twice for 10min. Then the gel was 
incubated for 1min with a 0.02% Sodium Thiosulfate solution, followed by 3 washing steps 
of the gel with MilliQ water for 30s. Staining was achieved by incubating the gel with a 
0.15% Silver Nitrate Solution for 30min, followed by a washing step with MilliQ water for 
1min. Colour development was achieved by using a 3% Sodium Carbonate and 0.05% 
Formaldehyde solution, the solution was poured onto the gel and shook until a brown 
precipitate formed, which was then discarded, and then fresh solution was poured onto the 
gel and shook until protein bands appeared. The colour development continues until a 5% 
Acetic Acid solution is added to stop the development. The gel was then washed with MilliQ 
water, scanned with GS-800™ Calibrated Densitometer and processed in ImageLab. 
The ZZ module in the ZZ-CBM64 fusion is able to bind to IgG antibodies (69). To check 
if ZZapo module, which is derived from a ZZ module, in the ZZapo-CBM64 fusion lost the 
IgG binding capacity, as required, another experiment was conducted. Both fusions were 
diluted to 10µM and spotted onto the control and test zones (ZZ-CBM64 and ZZapo-CBM64 
respectively) of the final µPAD design (Figure 8) using a 40nL needle (Schleicher & Schuell 
MicroCASTer 8-Pin System), the needle was washed in 5% Bleach, MilliQ water, 70% 
Ethanol and MilliQ water again. 10µL of PBS buffer was then used to wash the channel, 
followed by 15µL of IgG marked with Fluorescein Isothiocyanate (FITC 0.01µM) and 
incubated in the dark for 20min, washed again with 10 µL of PBS, and incubated in the dark 
again for 20min. The paper strips were then analysed in a microscope (Leica I3 Filter Cube, 
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LEJ EBQ 100 isolated power supply) and pictures were snapped using the software cellSens 
with an Olympus XC30 microscope camera. 
7.5 PREPARATION OF µPADS AND AUNPS  
The paper utilized in all the tests was Whatman no.1 chromatography paper (Product 
number: 3001-878; Whatman™, GE Healthcare©), in 250x250mm sheets with a thickness 
of 0.18mm, cut into A5 sheet size to fit the wax printer. The channels were designed using 
the software AutoCAD, which allows the design of precise 2D and 3D models. The patterns 
were designed black against a white background. The dimensions of the final channel design 
are represented on Figure 8. This channel allowed enough space for 0.5µL of sample in the 
test spots at once and showed an efficient flow of liquid, the thickness of the wax line is 
0.4mm. For spot assays, the channels had 8mm in diameter. For test velocity assays, the 
channels were 4.5cm long, 0.3cm wide and the spots had 0.6cm in diameter. 
 
Figure 8 - Final design and dimensions of the µPAD channels used in tests. 
The channels were printed using a Xerox ColorQube 8570 colour printer that prints wax. 
The print head dispenses ink (melted wax) on the surface of the paper, where it cools and 
solidifies instantaneously without further spreading. The components of the ink which are 
mainly hydrophobic carbamates, hydrocarbons and dyes, have a melting point around 
120°C. To melt these channels, two methods were used. The first one consisted in applying 
the paper directly onto a magnetic/heating plate (IKA RCT Classic) at 150ºC for about 2min, 
or until the wax was visibly melted through the paper uniformly. The second method was 
performed using an oven (BINDER FDL 115) at 150ºC and placing the sheets of paper on 
the racks for about 3-5min, which was a more convenient method as considerably more tests 
could be done at once, and the heat was evenly applied, allowing for a more even melting 
and spreading of the wax. Some tests use an adhesive membrane (Adhesives Research 
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Ireland Ltd; MH-93241-2) to cover the bottom of the paper strips, which allows for tests to 
be done on top of surfaces, as opposed to suspended. 
Gold nanoparticles (AuNPs) were prepared using the Naked Gold Conjugation Kit 
20nm and 40nm (BioPorto Diagnostics) according to manufacturer’s instructions for a pH 
of 7.8 using 4nm particles, which were conjugated with a mouse Anti-Apolipoprotein-A1 
IgG (Anti-Apo-A1, AntibodyShop). Unconjugated AuNPs were prepared the same way, 
using a volume of MilliQ water equal to the one used for antibodies in conjugated AuNPs, 
as well as stabilizing buffer to avoid aggregation of the nanoparticles. The process was done 
successfully if the solution remains red (Figure 9-A), or unsuccessfully if the solution turns 
grey, which indicates particle aggregation (Figure 9-B). 
 
Figure 9 – (A) Successfully antibody-conjugated AuNPs; (B) Unsuccessfully conjugated agregated AuNPs. 
All µPAD tests were done using 5pmol of ZZapo-CBM64 and Goat Anti-Mouse IgG 
pre-deposited in the test and control zones, respectively. The sample for Apo-A1 tests 
contained 10pmol of Apo-A1, along with 3µL of Anti-Apo-A1 antibody conjugated AuNPs, 
then running buffer is added to a total volume of 12 µL, incubated for 5min and added to the 
sample zone of the channel. When the tests do not contain Apo-A1, the same volume of 
AuNPs is used and 9µL of running buffer is added to a total volume of 12µL. A test where 
both the control and test zones of the µPAD show a signal is considered a positive test. If 
only the control zone has a signal, the test is considered negative. If the test zone presents a 
signal, but the control zone does not, the test is considered invalid. The control zone contains 
a Goat Anti-Mouse IgG (Ab-Goat, Nal Von Minden). The antigen detection was done using 
Human Apo-A1 (Sigma-Aldrich) as a model. All tests were ran in triplicates for more 
reliable results. 
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7.6   EVALUATION OF ZZAPO-CBM64 CAPTURE OF APOLIPOPROTEIN-A1 
The ability of the ZZapo-CBM64 fusion to capture Apo-A1 by was evaluated with two 
methodologies. First, a Basic Native Gel was done. The gel was prepared with a 10% 
acrylamide and bis-acrylamide total concentration. Samples of 15pmol of ZZapo-CBM64, 
Apo-A1 and Anti-Apo-A1 monoclonal antibody were diluted to a final volume of 15µL, let 
incubate for 10min and then 10µL of loading buffer (40% Glycerol, 12.5% 0.5M Tris-HCl 
pH 6.8, bromophenol blue traces) was added to the samples, which were then loaded onto 
the gel. It was run at 80V for 3h30 in running buffer (0.6% Trizna, 2.6% Glycine, pH 8.9) 
and then stained with Silver Nitrate, as described in the previous section. The gel was then 
washed with MilliQ water, scanned with GS-800™ Calibrated Densitometer and processed 
in ImageLab.  
To further confirm the results from the Native Gel, another experiment was conducted 
using cellulose microparticles like the one described in the previous section. Samples of 
20pmol of ZZapo-CBM64, Apo-A1 and Anti-ApoA1 monoclonal antibody were diluted to a 
final volume of 15µL using PBS and let incubate for 10min at RT on a shaker (VWR Digital 
Vortex Mixer), after which 20µL of a 20µM micro-cellulose particles (type 20 diluted in 
PBS) suspension was added and incubated again for 10min on a shaker at RT. The mixture 
was then centrifuged at 2000g for 5min and a 20µL sample of each was submitted to SDS-
PAGE, as described in section 7. The resulting gel was stained with Silver Nitrate washed 
with MilliQ water, scanned with GS-800™ Calibrated Densitometer and processed in 
ImageLab. 
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8   RESULTS AND DISCUSSION 
8.1 DESIGN, CONSTRUCTION AND SEQUENCING OF ZZAPO-CBM64 
The first goal of this thesis was to design and construct a bi-functional protein fusion 
that combines a ZZapo affibody with affinity towards Apo-A1 with a CBM64 from S. 
thermophile with affinity towards cellulose. The sequence of the corresponding gene was 
designed on the basis of the sequences found in the literature (4,117). A hexa-histidine tag 
was included in the fusion to facilitate purification (Figure 6 and 7). The cloning of the 
desired sequence in a pET21a plasmid was outsourced to NZYTech. E.coli cells were then 
transformed with the resulting construct. The plasmid was then amplified by growing cells, 
purified using a NZYMiniprep Kit and sent to sequencing to confirm cloning. A plasmid 
solution with a concentration of 190ng/µL and ratios of absorbance of 1.939 for 
Abs260/Abs280 and of 2.065 for Abs260/Abs230 was obtained from the NZYMiniprep Kit. The 
Abs260/Abs280 ratio indicates protein contamination in nucleic acids, and in pure DNA should 
be around 1.8; thus, the obtained purified DNA, which showed a Abs260/Abs280 ratio of 
1.939, does not have significant protein contaminations. The Abs260/Abs230 ratio indicates 
contamination of organic compounds, and should be around 2.0 for pure DNA; thus, the 
obtained purified DNA, which showed a Abs260/Abs230 ratio of 2.065, is not contaminated 
by organic compounds.   
In order to confirm if the plasmid construct contained the ZZapo-CBM64 module 
(Figure 6), one sample of purified DNA was incubated with the restriction enzymes XhoI 
and XbaI, and another sample was incubated with just XbaI. These enzymes should cut the 
plasmid in an unique site, and when acting together should isolate the ZZapo-CBM64 module 
(800 bp) from the vector backbone. Digested samples, along with a MW marker and an 
undigested plasmid were analysed by electrophoresis in a 1% agarose gel, which was stained 
with ethidium bromide (Figure 10). The undigested plasmid in lane 2 is characterized by two 
bands, which correspond to the relaxed (>10000 bp) and supercoiled (~5000 bp) isoforms of 
the plasmid. As expected, the DNA sample digested with XbaI in lane 3 contains a single 
band (~6100 bp), which corresponds to the linearized form of the plasmid. Lane 4 contains 
the DNA sample digested with both XhoI and XbaI. A first band with <6000 bp is seen that 
corresponds to the vector backbone. This band migrates slightly faster than the one observed 
in Lane 3. A second band is barely visible at 800bp that corresponds to the excision of a 
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fragment containing the ZZapo-CBM64 module by both restriction enzymes. These results 
confirm that a fragment in the plasmid with a size and location compatible with the ZZapo-
CBM64 is present. Furthermore, the linearized form (lane 3) migrates slower than the major 
band observed in lane 4, since the latter has an excised fragment, which was expected. Even 
though the isoforms present in lane 2 have the same weight, their conformations are 
different. The supercoiled form migrates faster than the relaxed since it more easily moves 
through the gel. 
Having confirmed that a fragment is present in the plasmid with a size and location 
compatible with the ZZapo-CBM64 module, the purified plasmid DNA was sent for 
sequencing to Stabvida with two primers that were selected about 150bp before and after the 
sequence. The sequence was obtained in both forward and reverse sequencing to confirm 
possible mismatches. If errors emerge that are present in both sequences, then the mismatch 
must be real. The quality of the sequencing data is represented in Figure 11, where the first 
graph is the Forward sequence, and the second is the Reverse sequence. 
 
Figure 10 – Agarose gel stained with ethidium bromide of: 1) Molecular weight marker; 2) Undigested purified plasmid; 
3) Purified plasmid digested with XbaI; 4) Purified plasmid digested with XhoI and XbaI. 
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Figure 11 – Quality of sequencing data provided by Stabvida of the forward sequencing (first graph) and reverse sequencing 
(second graph). 
As previously mentioned, the sequence of interest starts at about 150bp in both the forward 
and reverse sequences, where the primers were selected. In both graphs of Figure 11 we can 
observe that the first 100bp of each sequence have considerably lower quality than the 
following bps, and the reverse sequence (second graph) has a better overall quality than the 
forward sequence (first graph). Both sequences were analysed in Olygoanalyser for 
mismatches with the original ZZapo-CBM64 module sequence, which did not show any 
mismatches in this area (Figure 12). 
 
Figure 12 – Representation of the sequences obtained by Stabvida, seq R is the reverse sequence, seq fwd is the forward 
sequence, ZZapo-CBM64 is the sequence of the original ZZapo-CBM64 module in the plasmid. Mismatches of the seq R 
and seq fwd sequences are marked with black lines in these sequences. 
The data from all the sequences is shown in Figure 12 where seq R is the reverse 
sequence, seq fwd is the forward sequence and ZZapo-CBM64 is the original ZZapo-CBM64 
module sequence (Figure 6). The bars representing each sequence are aligned, meaning that 
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the location of the bars represent the location of the actual sequence. The black lines in the 
forward and reverse sequences correspond to mismatches. Since these mismatches were not 
found simultaneously in the forward and reverse sequences, the mismatches are not real. 
Furthermore, the part containing the ZZapo-CBM64 sequence did not show any mismatches, 
confirming that the produced ZZapo-CBM64 had the expected sequence. Thus, any eventual 
inability of ZZapo-CBM64 to capture Apo-A1 will not be attributable to an incorrect 
synthesis of the ZZapo-CBM64 construct. 
 
8.2 PURIFICATION AND QUANTIFICATION OF ZZAPO-CBM64  
Protein purification was achieved by using metal affinity chromatography with a 
Niquel Sepharose 6 Fast Flow column in an ÄKTApurifier 10 system. This column was used 
because the fusion protein contains an exposed Histidine tag in its C-Terminus, which forms 
complexes with Ni2+ ions immobilized in the resin, allowing the selective binding of these 
proteins. Imidazole is a competitive binder to the ions, and is used in all the elution buffers, 
although in low concentrations, to avoid or wash away non-specific binding. The elution 
buffer has a higher concentration of imidazole to elute away the purified protein, as it 
competitively binds to the ions in the resin. Figure 13 shows a chromatogram of a 
representative run of ZZapo-CBM64 purification. Two major peaks of absorbance at 280nm 
are noted. The first corresponds to the flow of unbound proteins that didn’t bind specifically 
to the Ni2+ ions, whereas the second peak corresponds to the elution of ZZapo-CBM64, which 
was separated in two pools. The pool with higher concentration (Fraction A) was recovered 
from the fractions 23mL to 26mL, and the second pool (Fraction B) was recovered from the 
fractions 26mL to 34mL. Fractions A and B are highlighted in Figure 13 in red and green 
respectively. The first fractions of purified ZZapo-CBM64 recovered after the 
chromatography had a higher concentration, as confirmed by the peak in Abs280nm 
highlighted in a red rectangle in Figure 13. However, the protein was continually eluted at 
lower concentrations until the end of the run (highlighted in a green rectangle in Figure 13). 
Since we wanted a concentrated ZZapo-CBM64 solution, we separated the eluted protein 
fractions in two pools, A and B, so as not to dilute the highly concentrated fractions. Other 
purification runs were done when the pools of ZZapo-CBM64 ran out. These runs had a 
similar chromatogram (results not shown). 
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Figure 13 - Purification of ZZapo-CBM64 fusion was achieved by metal affinity chromatography with a Niquel Sepharose 
6 Fast Flow column. The column was equilibrated with 5 column volumes of buffer A (10 mM Imidazole, 50 mM 
NaHEPES pH 7.5; 1 M NaCl, 5 mM CaCl2) and the clarified E.Coli lysate was loaded in the column. The unbound proteins 
were eluted with 20 volumes of buffer A and the ZZapo-CBM64 protein was eluted with 10 volumes of buffer B (300 mM 
Imidazole, 50 mM NaHEPES pH 7.5; 1 M NaCl, 5 mM CaCl2). The chromatogram was obtained by reading the absorbance 
at 280 nm. The second peak in the Abs280 line corresponds to the eluted fusion protein. The recovered Fractions A and B 
are highlighted in red and green respectively. 
 
To evaluate the purity of the extracted fractions, an SDS-PAGE was performed. The 
resulting gel is shown in Figure 14. The first lane in the gel of Figure 14 corresponds to a 
250kDa molecular weight standard (Bio-Rad). Lane 2 is a sample of the cell lysate 
containing the fusion protein loaded into the Niquel Column. Lane 3 represents a sample of 
the first fractions collected in the elution (first 5mL from elution). Lanes 5 and 7 are a sample 
of the purified ZZapo-CBM64 fractions A and B respectively (24.47kDa), which show no 
other impurities in the gel. The band represented in lane 7 is smaller due to its lower 
concentration. For comparison purposes, lane 9 was run with a purified ZZ-CBM64 sample, 
which is slightly lighter than the other construct (24.16kDa). The remaining lanes were filled 
with loading buffer diluted in the same volume as the samples, to avoid stretching of bands 
due to density differences.  
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Figure 14 - Coomassie Blue Stained SDS-PAGE analysis of the purification of ZZapo-CBM64 Lanes: 1) 250kDa molecular 
weight standard; 2) E.Coli lysate sample loaded onto the Niquel Sepharose 6 Fast Flow column; 3) Flow-through sample; 
5) Purified ZZapo-CBM64 faction A; 7) Purified ZZapo-CBM64 faction B; 9) Purified ZZ-CBM64. 
To quantify the protein in fractions A and B, the BCA Assay was used. Bovine Serum 
Albumin Standards of known concentration were prepared in the Buffer B used in the 
purification of the construct to avoid any differences in absorbance caused by the difference 
of buffers, read at 562nm along with purified fractions A and B and plotted and linearized 
(Figure 15). 
 
Figure 15 - Graphic representation of the prepared BSA standards concentrations versus their Absorbance at 562nm, along 
with the normalization of those values and its linearization, equation of the linearization and Coefficient of Determination 
(R2). 
36 
  
Using the equation provided by the linearization, the concentration of fractions A 
and B were calculated using their Abs562nm. The calculated concentrations were 320.7µg/mL 
and 80.3µg/mL respectively, which correspond to a molarity of 13.1µM and 3.28µM 
respectively. The Coefficient of Determination (R2) value is also a good indicator that the 
determined linearization was accurate. 
8.3  COMPARISON OF ZZAPO-CBM64 WITH ZZ-CBM64 
The ZZapo affibody was derived from the ZZ module by changing a number of amino 
acids in such a way that the affinity of ZZ towards the Fc portion of IgG antibodies is lost 
and the affinity towards Apo A1 is obtained (4). A few tests were thus conducted to check 
if the new ZZapo affibody retained some of the ability of the ZZ module to recognize IgG 
antibodies. These tests were performed using the ZZapo-CBM64, and ZZ-CBM64 constructs. 
The ability of the CBM64 modules in the fusions to bind to cellulose was also assessed.  
First, the cellulose binding capacity of the CBM64 portion was assessed by incubating 
the fusions with cellulose microparticles or a piece of cellulose paper separately, centrifuging 
the mixtures and analyzing the supernatant by SDS-PAGE. The binding of the fusions to 
cellulose during the incubation should produce a supernatant free of protein upon 
centrifugation. The SDS-PAGE analysis of then resulting centrifuged supernatants is shown 
on Figure 16. Lanes 1 and 2 of the gel correspond to ZZ-CBM64 and ZZapo-CBM64 
respectively, before adding cellulose, for control. Lanes 4 and 5 represent the centrifuged 
supernatant obtained after incubation of ZZ-CBM64 and ZZapo-CBM64 respectively with 
cellulose particles, and lanes 7 and 8 represent the centrifuged supernatant obtained after 
incubation of ZZ-CBM64 and ZZapo-CBM64 respectively with cellulose paper. Because no 
protein was detected on lanes 4, 5, 7 and 8, we can assume that the molecules were captured 
by the cellulose in both cases. This is in accordance with the expected results, proving the 
high affinity of the ZZapo-CBM64 and ZZ-CBM64 constructs to cellulose. The remaining 
lanes were filled with loading buffer to avoid stretching of bands due to differences in 
density. All lanes show 2 bands on the initial part of the gel, which could be caused by some 
impurity present in the loading buffer, due to improperly washed material or some 
contamination during the preparation of the loading buffer. 
37 
  
 
Figure 16 - Testing of the affinity of ZZ-CBM64 and ZZapo-CBM64 fusions towards cellulose. Cellulose microparticles 
and cellulose paper were incubated with the fusions and removed by centrifugation. The supernatants were then analysed 
by SDS-PAGE. Lanes: 1) ZZ-CBM64;  2) ZZapo-CBM64; 4) Supernantant of ZZ-CBM64 incubation and centrifugation 
with cellulose particles; 5) Supernantant of ZZapo-CBM64 incubation and centrifugation with cellulose particles; 7) 
Supernantant of ZZ-CBM64 incubation and centrifugation with cellulose paper; 8) Supernantant of ZZapo-CBM64 
incubation and centrifugation with cellulose paper. 
The ability of the two fusions to capture IgG antibodies was tested next. Tests were 
performed by dispensing a specific amount of each fusion onto the control and test zones of 
a µPAD. Following washing with buffer, a solution of an IgG antibody labelled with FITC 
was ran through the µPAD, incubated, washed with buffer again, incubated and analysed on 
a microscope for fluorescent signals. Antibody capture by either fusion should result in a 
fluorescent signal over the area where the molecules were spotted. 
 
Figure 17 – Testing of the affinity of ZZ-CBM64 and ZZapo-CBM64 fusions towards IgG antibodies. Tests were performed 
by dispensing specific amounts of each fusion on distinct locations within a µPAD channel. A solution of an IgG antibody 
labelled with FITC was ran through the µPAD and test zones were imaged by fluorescence microscopy. A) Blanc (no 
molecules spotted); B) ZZ-CBM64 was spotted before incubation; C) ZZapo-CBM64 was spotted before incubation. 
Figure 17 represents the snapshots of µPAD zones where ZZ-CBM64 (Figure 17-B) 
and ZZapo-CBM64 (Figure 17-C) were added. A control zone was also imaged (Figure 17-
A). The results show that the ZZ-CBM64 fusion successfully captured the labelled IgG 
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antibodies as expected, as judged by the brighter fluorescence spot on the matrix, where the 
fusion was dispensed (Figure 17-B). On the contrary, no fluorescence signal was detected at 
the site where the ZZapo-CBM64 was dispensed (Figure 17-C). This confirms that the ZZapo 
affibody is not able to recognize IgG antibodies as expected, as it was designed to 
specifically bind to Apo-A1. 
8.4 PREPARATION OF µPAD TESTS 
Three main designs of lateral flow tests were made and tested to determine the optimal 
flow of sample and the optimal volume of liquid necessary to spot the control and test areas. 
These designs are represented on Figure 18. 
 
Figure 18 – Designs of the µPAD tests tested for optimization of sample flow and reagent spotting until the final obtained 
design (C). 
 The general design shows three areas to spot the samples and a reservoir for flow-
through, the whole area of the test holds about 25 µL of volume at a time, however, 
additional washes can be made if a piece of paper is held on top of the flow-through area, as 
it will adsorb the excess buffer. Control (c) and test (t) areas hold 0.5 µL of liquid at a time, 
additional volumes can be added 0.5 µL at a time after the previous spot has dried 
completely. This is necessary to limit the distribution of molecules to the desired area. The 
first area is to introduce the sample into the µPAD. The first design (Figure 18-A) showed a 
very rapid flow rate, which can be problematic since the c and t areas are less time exposed 
to the sample, and the c and t areas were not well defined after melting, causing spotted 
molecules to flow out of the desired area. On the second design (Figure 18-B) the channel 
reduced in width, shower a better flow rate, and more defined c and t areas, however after 
melting they became too small to hold the desired volume for spotting. The area to spot the 
sample was also re-designed to allow faster adsorption and to facilitate the flow. The final 
design (Figure 18-C) had adjustments made to the c and t areas to hold the desired volume 
of spotted molecules. 
 These paper devices should not be placed in direct contact with a bench surface when 
running a test to prevent the migrating liquids to wet the surface. Rather, the device should 
be suspended to allow liquid to hang freely beneath the paper surface. This effect can be 
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observed in the control and test zones shown in Figure 19. However, if the devices are not 
suspended in such a way as to guarantee a perfectly horizontal surface, the liquid may take 
a longer time to migrate across the channels. Having the test being run on a flat surface could 
make it more reliable and easy. With this in mind, an adhesive membrane was applied to the 
bottom of the test paper strips, opposite to the side where the channel was printed, to enable 
the running of tests on a flat surface. A number of experiments tests were then made to 
determine the influence of the adhesive membrane in the migrating velocity of fluids through 
the µPAD, as well as any other unexpected effects that could occur. 
 
Figure 19 – Lateral view of a suspended µPAD test. Liquid drops are seen hanging below the paper strip in the control 
and test zones. 
 In the first set of experiments conducted, a sample containing food dye diluted in 
running buffer was run through two µPADs, one with an adhesive membrane beneath and 
another suspended (Figure 20-A). An observation of the devices shows that the dye migrated 
through the channels with velocity inferior to the velocity of the liquid (Figure 20-A). 
Nevertheless, the liquid front was still visible and allowed the recording of the migration 
distance as a function of time (Figure 20-B). The results show that liquids running in µPADs 
using a bottom adhesive layer moved considerably faster than in those without adhesive. 
According to the Washburn’s equation, which describes capillary flow, the time t required 
for a liquid of dynamic viscosity η and surface tension γ to penetrate a distance L in the 
channel, is proportional to the square of L, where D is the pore Diameter: 
𝑡 =
4𝜂
𝛾𝐷
𝐿2 
From the linearization of this equation (Figure 20-B) we can further confirm that the tests 
using the adhesive membrane have higher slopes than those without the membrane, 
translating into a higher velocity of flow. 
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Figure 20 – A) Sample velocity tests of a mixture of food coloring and PBS buffer in µPADs with and without an adhesive 
membrane. B) Linearization of Washburn’s equation using the times of the front of the run vs the distance marked on the 
paper strips with blue dots.  
 In a second set of experiments, the migration of plain AuNPs and of AuNPs 
conjugated with the anti-Apo-A1 antibody was compared in µPADs without and with 
adhesive membrane. From this point forward, unless stated otherwise, all tests were run with 
5pmol of Ab-Goat in the control area and 5pmol of ZZapo-CBM64 diluted in running buffer 
to a total volume of 1 µL in the test area. The first tests showed that the migration of 
conjugated AuNPs was hampered in both µPADs with and without adhesive membrane due 
to unspecific binding to the cellulose microfibrils (Figure 21-A1, B1). To remove this 
unwanted binding, the surfactant Tween 20, which is a blocker commonly used to remove 
non-specific binding, was added to the buffer at a concentration of 0.05% (v/v).  
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Figure 21 - µPADs with (A1, A2, A3) and without (B1, B2, B3) adhesive membrane on the bottom, ran with ZZapo-CBM64 
in the test zone and Goat anti-mouse antibody in the control zones, with samples containing: A1) Conjugated AuNPs diluted 
in PBS buffer; B1) Conjugated AuNPs diluted in PBS buffer; A2) Unconjugated AuNPs diluted in PBS buffer with 0.05% 
Tween20; B2) Unconjugated AuNPs diluted in PBS buffer with 0.05% Tween20; A3) Conjugated AuNPs diluted in PBS 
buffer with 0.05% Tween20; B3) Conjugated AuNPs diluted in PBS buffer with 0.05% Tween20. 
As shown in Figure 21-A2, A3, B2 and B3, after the addition of Tween 20 in the 
buffer, the AuNPs flowed through the channel and did not bind to the cellulose before 
reaching the test zones. Furthermore, the use of the adhesive membrane did not have any 
noticeable impact on the migration across the test strips (Figure 21-A2, A3). Thus, µPADs 
with adhesive on the bottom were used in all subsequent tests. As expected, the AuNPs 
conjugated with the mouse Anti-Apo-A1 antibody were captured at the control site by the 
pre-deposited anti-mouse goat antibody, as judged by the presence of a red spot on the 
control zone of the µPADs (Figure 21-A3, B3). However, non-specific binding between 
ZZapo-CBM64 in the test zone with conjugated AuNPs (Figure 21-A3, B3) was detected. A 
similar result was obtained when running unconjugated AuNPs (Figure 21-A2, B2), which 
indicates that the non-specific binding is due to a nanoparticle-ZZapo-CBM64 interaction, 
and not due to the Anti-Apo-A1 antibody. One way to address this problem would be to 
change the composition of buffer used in the tests. The first option was to increase the 
concentration of Tween 20. However, high concentrations of Tween 20 could not be used 
because the surfactant tends to permeabilize the wax walls. To assess at which concentration 
this happens, tests were made in circular areas bounded by wax circumferences using a dye 
solubilized in buffers with concentrations of Tween 20 ranging from 0.05-0.25% (v/v). 15 
µL of these solutions were dispensed over the circular areas 5µL at a time, with drying in 
between. The results in Figure 22 show that concentrations of Tween 20 higher than 0.15% 
will cause leakage of fluids through the wax walls, and thus cannot be used in running 
buffers.  
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Figure 22 – Spot assays of a dye solution mixed with PBS buffer with varying concentrations of Tween20: 1) 0.05% 
Tween20; 2) 0.08% Tween20; 3) 0.1% Tween20; 4) 0.12% Tween20; 5) 0.15% Tween20; 6) 0.17% Tween20; 7) 0.2% 
Tween20; 8) 0.25% Tween20. 
Experiments were then performed with buffers with Tween 20 concentrations lower 
than 0.15% to see if they removed the unwanted binding. µPADs were ran with conjugated 
AuNPs diluted in running buffer and ran through the LFA, washing the channel twice with 
the same buffer. From the results shown in Figure 23-b to Figure 23-f we can observe that 
the increased concentration of Tween 20 did not remove the unwanted non-specific binding 
at the used concentrations, so another approach must be used. 
 
Figure 23 - µPADs with adhesive membrane ran with ZZapo-CBM64 in the test zone and Goat anti-mouse antibody in the 
control zones, the sample ran contained Anti-Apo-A1 conjugated AuNPs diluted in PBS buffer with varying concentrations 
of Tween20. 
 Bovine Serum Albumin (BSA) is another commonly used protein blocker in protein 
assays, and it was used in the running buffer at a concentration of 0.1% (w/v), along with 
0.08% Tween 20. A few different methodologies were used to evaluate the most efficient 
way of removing the non-specific interactions. The resulting tests are shown in Figure 24. 
In Figure 24-A the test was run in the same way as the previous ones, but the washing step 
and dilution of conjugated AuNPs was done using the new buffer containing BSA. Figure 
24-B shows a similar test but with an additional pre-washing step with the new buffer, after 
dispensing the ZZapo-CBM64 and goat anti-mouse antibody in the test and control areas, 
respectively, and before running the sample through the test. The example in Figure 24-C, 
ZZapo-CBM64 was incubated in the new buffer for 5min before spotting it into the test area, 
and then run in the same way as shown in Figure 24-A. In the example shown in Figure 24-
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D, we used BSA conjugated AuNPs, where 100µL of conjugated AuNPs were incubated 
with 100µL of a 0.1% BSA solution for 20min, centrifuged and the pellet was resuspended 
in the buffers used for AuNP functionalization to a final volume of 100µL. The test was run 
in the same conditions as the first one. Tests shown in Figure 24-E and 24-F were done using 
the same methodology as in the ones shown in Figure 24-C and 24-D respectively, but with 
the additional pre-washing step used in the case of the test of Figure 24-B. From the resulting 
tests, we can see that a combination of pre-washing the channels with AuNPs conjugated 
with BSA or ZZapo-CBM64 conjugated with BSA were the only methodologies that 
efficiently eliminated the non-specific capture of AuNPs by ZZapo-CBM64. The other tests 
(Figure 24-A-D) all showed a positive signal in the test zone, although it was considerably 
less intense than when using a running buffer without BSA, as it blocks binding sites of the 
molecules creating competitive binding. The running buffer to be used from this point 
forward is PBS, 0.08% Tween 20 and 0.1% BSA, as well as BSA conjugated AuNPs, which 
can be conjugated in a batch, and the µPAD channels will be pre-washed with this buffer 
before running a sample. 
 
Figure 24 - µPADs ran with ZZapo-CBM64 in the test zone and Ab-Goat in the control zones, the sample ran contained 
Anti-Apo-A1 conjugated AuNPs diluted in PBS buffer with 0.1% BSA and 0.08% Tween20. A) the buffer was used in the 
sample dilution; B) The channel was pre-washed with the buffer before adding the sample; C) ZZapo-CBM64 was incubated 
with the buffer before spotting the test zone; D) BSA conjugated AuNPs were used in the sample; E) ZZapo-CBM64 was 
incubated with the buffer before spotting the test zone and the channel was pre-washed with the buffer; F) BSA conjugated 
AuNPs were used in the sample and the channel was pre-washed with the buffer. 
8.5 CAPTURE AND DETECTION OF APOLIPOPROTEIN-A1 
µPAD tests with and without adhesive membrane were conducted to evaluate the 
capture and detection of Apo-A1 by ZZapo-CBM64 and Anti Apo-A1 and BSA conjugated 
AuNPs (Figure 25). AuNPs were incubated with Apo-A1 and running buffer for 10min, 
while ZZapo-CBM64 and control antibody were spotted into the test and control areas of the 
µPAD, using the buffer to pre-wash the channel once the spots were dried. The ratio of Apo-
A1 to ZZapo-CBM64 was 2:1, to assure enough Apo-A1 reached the test zone. 
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Figure 25 - µPADs ran with ZZapo-CBM64 in the test zone and Ab-Goat in the control zones, the sample ran contained 
Anti-Apo-A1 and BSA conjugated AuNPs and Apo-A1, diluted in: A) PBS buffer with 0.1% BSA and 0.08% Tween20, 
using an adhesive membrane on the bottom of the paper strip; B) PBS buffer with 0.1% BSA and 0.08% Tween20, without 
the adhesive membrane on the bottom of the paper strip; : C) NH4HCO3 10mM buffer with 0.1% BSA and 0.08% Tween20, 
using an adhesive membrane on the bottom of the paper strip; D) NH4HCO3 10mM buffer with 0.1% BSA and 0.08% 
Tween20, without the adhesive membrane on the bottom of the paper strip. 
From the tests we can see that Apo-A1 does not seem to be captured in the test zone by 
ZZapo-CBM64, as there is no noticeable signal (Figure 25). Furthermore, the use of the 
adhesive membrane caused some interaction with Apo-A1 holding the sample in the channel 
before reaching the test zone, as shown by the AuNPs in this area (Figure 25-A-B). This 
effect was not as significant in suspended tests without the adhesive membrane and could be 
eliminated with a change of running buffer. This was tested by using the buffer NH4HCO3 
(10mM, pH 7.4), as it was the buffer used by Sigma-Aldrich in the purified Apo-A1, with 
0.08% Tween20 and 0.1% BSA (Figure 25-C-D). The use of this new buffer completely 
removed the retention of the sample in the initial part of the test in both µPADs with and 
without the adhesive membrane. Apo-A1 detection was not accomplished in either case, 
which could mean that the ZZapo-CBM64 construct is not capturing Apo-A1 as intended. 
To determine if Apo-A1 capture is not occurring, two methodologies were used. 
First, samples of these molecules were incubated and ran through a Basic Native-PAGE. 
Several gels were run with different conditions (mainly with different voltages, running time 
and buffer pH), and the best resulting gel is presented in Figure 26. Lanes 1, 2 and 3 represent 
ZZapo-CBM64, Apo-A1 and Anti-Apo-A1 respectively. Lane 5 represents a mixture of 
ZZapo-CBM64 and Apo-A1, lane 7 is a mixture of Apo-A1 and Anti-Apo-A1, lane 9 
represents a mixture of all three molecules and lanes 4, 6, 8 and 10 were loaded with loading 
buffer to maintain the same density in all lanes, some bands can be observed from leakage 
from other wells. Although the results are not highly conclusive, they provide some insight 
into the interactions between the molecules. In lane 5 we can clearly see the band 
corresponding to ZZapo-CBM64 between two other less visible bands representing Apo-A1. 
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If these molecules interacted, a different band would be visible representing the complex. 
Since this was not the case, the ZZapo-CBM64 construct was likely not capturing Apo-A1. 
In lane 7 we can clearly see the bands that correspond to Anti-Apo-A1, however the bands 
for Apo-A1 are not visible, which indicates that Anti-Apo-A1 was successfully capturing 
Apo-A1. In this case a different migration pattern is not expected since the antibody is very 
large and does not migrate far into the gel. Finally, in lane 9 bands representing ZZapo-
CBM64 and Anti-Apo-A1 are visible, but not the one for Apo-A1, indicating that the intended 
complex of the three molecules was not formed likely due to ZZapo-CBM64 being unable to 
capture Apo-A1. 
 
Figure 26 – Testing of the affinity ZZapo-CBM64 fusion towards Apo-A1, as well as Anti-Apo-A1 antibody affinity to 
Apo-A1. The mixtures were incubated, loading buffer was added and the mixtures were then analysed by Native-PAGE. 
Lanes: 1) ZZapo-CBM64; 2) Apo-A1; 3) Anti-Apo-A1; 5) Mixture of ZZapo-CBM64 and Apo-A1; 7) Mixture of Apo-A1 
and Anti-Apo-A1; 9) Mixture of ZZapo-CBM64, Apo-A1 and Anti-Apo-A1. 
To further validate the results observed in the Native PAGE, a cellulose binding test 
was done by incubating samples of ZZapo-CBM64, Apo-A1 and Anti-Apo-A1 antibody with 
cellulose microparticles, centrifuging and running the supernatant through SDS-PAGE 
(Figure 27). If any protein binds to ZZapo-CBM64, then the complex will sink to the bottom 
along with the cellulose particles and not be present in the supernatant. All mixtures were 
done in 1:1 ratios and diluted equally. 
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Figure 27 - Silver Stained SDS-PAGE of cellulose affinity test using ZZapo-CBM64 of: 1) ZZapo-CBM64;  2) Apo-A1; 3) 
Anti-Apo-A1; 5) Supernatant of ZZapo-CBM64 incubation and centrifugation with cellulose particles; 7) Supernantant of 
the incubation and centrifugation of the mixture of Apo-A1 and ZZapo-CBM64 with cellulose particle; 9) Supernantant of 
the incubation and centrifugation of the mixture of Apo-A1, Anti-Apo-A1 and ZZapo-CBM64 with cellulose particles. 
Lane 1 corresponds to ZZapo-CBM64 which looks deformed because the gel was slightly 
malformed, while Lane 2 was attributed to Apo-A1, and Lane 3 to Anti-Apo-A1 antibody, 
all diluted in PBS buffer. Lanes 4, 6, 8 and 10 were loaded with diluted running buffer, to 
avoid density differences between lanes. Lane 5 represents ZZapo-CBM64 after incubation 
with cellulose nanoparticles, the lack of signal meaning it successfully bound to the particles, 
as expected. Lane 7 represents a mixture of ZZapo-CBM64 and Apo-A1 after the incubation 
with cellulose, resulting in a band corresponding to Apo-A1, which means that in these 
conditions, ZZapo-CBM64 is not capturing Apo-A1 as intended. Lane 9 represents a mixture 
of all molecules after incubation with cellulose, resulting in three bands, the first two 
corresponding to Anti-Apo-A1, and the last one representing Apo-A1. From these results we 
can conclude that the ZZapo-CBM64 complex is not capturing Apo-A1. There also should 
be no interaction between Anti-Apo-A1 and ZZapo-CBM64 since the band remains after the 
incubation with cellulose. Another cellulose binding experiment was done where the 
mixtures were incubated in different pH buffers and with different times to assess if different 
incubation conditions could promote Apo-A1 capture by ZZapo-CBM64, the resulting gels 
are presented in Figure 28. 
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Figure 28 - Silver Stained SDS-PAGE of cellulose affinity test using ZZapo-CBM64 of: A-1) Apo-A1;  A-2) ZZapo-CBM64; 
A-3) Anti-Apo-A1; A-4) Mixture of ZZapo-CBM64 and Apo-A1 in PBS pH 7.6; A-5) Mixture of ZZapo-CBM64, Apo-A1 
and Anti-Apo-A1 in PBS pH 7.6; A-6) Mixture of ZZapo-CBM64 and Apo-A1 in PBS pH 8.6; A-7) Mixture of ZZapo-
CBM64, Apo-A1 and Anti-Apo-A1 in PBS pH 8.6; A-8) Mixture of ZZapo-CBM64 and Apo-A1 in PBS pH 9.6; A-9) 
Mixture of ZZapo-CBM64, Apo-A1 and Anti-Apo-A1 in PBS pH 9.6; B-2) Mixture of ZZapo-CBM64 and Apo-A1 in PBS 
pH 7.6 incubated overnight; B-4) Mixture of ZZapo-CBM64, Apo-A1 and Anti-Apo-A1 in PBS pH 7.6 incubated overnight; 
B-6) Mixture of ZZapo-CBM64 and Apo-A1 in PBS pH 7.6 incubated for 2h; B-8) Mixture of ZZapo-CBM64, Apo-A1 and 
Anti-Apo-A1 in PBS pH 7.6 incubated for 2h. 
 Lane A-1 represents Apo-A1, lane A-2 represents ZZapo-CBM64, lane A-3 
represents Anti-Apo-A1. In all the lanes of both gels, more bands appeared than what was 
expected, one band for A-1 and A-2 and two bands for A-3. This effect has been previously 
studied by other authors (118), and are most likely fragments resulting from the sample 
preparation process for SDS-PAGE. These authors found that longer incubation at 100ºC 
times and high concentrations of DTT can cause fragmentation and the addition of an 
alkylating agent, such as iodoacetamide or N-ethylmaleimide, could reduce this effect. The 
experiment was not repeated with these alkylating agents due to limited sample size of Apo-
A1 and Anti-Apo-A1. Lanes A-4, A-6 and A-8 represent mixtures of ZZapo-CBM64 and 
Apo-A1 in PBS pH 7.6, 8.6 and 9.6 respectively, and lanes A-5, A-7 and A-9 represent 
mixtures of ZZapo-CBM64, Apo-A1 and Anti-Apo-A1 in PBS pH 7.6, 8.6 and 9.6 
respectively. Lanes B-2 and B-6 represent mixtures of ZZapo-CBM64 and Apo-A1 in PBS 
pH 7.6 incubated overnight and for 2h respectively, and lanes B-4 and B-8 represent 
mixtures of ZZapo-CBM64, Apo-A1 and Anti-Apo-A1 in PBS pH 7.6 incubated overnight 
and for 2h respectively. From this experiment we can conclude that no matter the incubation 
conditions, the capture of Apo-A1 by ZZapo-CBM64 was not achieved since in all cases 
Apo-A1 is present in the supernatant after the incubation with ZZapo-CBM64 and cellulose 
particles. As expected there was also no interaction between ZZapo-CBM64 and Anti-Apo-
A1, since the antibody is present in all cases and did not bind to ZZapo-CBM64 or the 
cellulose particles.  
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To discover the reason why ZZapo-CBM64 is not capturing Apo-A1, further studies 
should be made. One hypothesis is that the 3D structure of the construct could be folded in 
such a way that covers the part that recognizes and binds Apo-A1, making it unable to 
interact with the affibody, however this hypothesis could not be tested. 
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9 CONCLUSION 
Antibodies are the main affinity molecule of choice for biochemical immunological 
applications, due to the extensive knowledge already available. These molecules, however 
present some limitations due to their molecular structure. As such, recent efforts have been 
made to discover new affinity molecules with simpler structures and high affinities. 
Affibodies are one of these novel affinity proteins, and have already been applied in several 
fields such as imaging, diagnostics, therapies, bioassays and biosensors. Furthermore, 
affibodies are also a great alternative to antibodies due to simpler and cheaper synthetization 
methods, as well as showing versatility, not only in immunoassays, but also in imaging, 
therapeutics, protein purification and other bioassays. Affibodies can target several 
molecules, such as Apo-A1 which has been discovered to be involved in several 
immunomodulatory effects, and further understanding of these technologies could provide 
novel advances in therapeutics and diagnostics.  
POC testing has come to revolutionize molecular testing, since it has the potential of 
delivering diagnostic results rapidly, while also being simple, inexpensive, disposable and 
portable, so it is vital that these technologies are further developed for implementation. POC 
technologies include microfluidic devices such as µPADs, which present exceptional 
versatility due to their capacity of being composed of different materials, involving different 
kinds of detection and fabrication methods, as well as flexible and extremely customizable 
designs to suit whatever necessity the user needs, as reviewed in many works throughout 
this paper. These tests are made up of paper matrixes with hydrophobic barriers as the test 
medium, which considerably reduces prices, is easily disposable and portable, amounting to 
an exceptional device in resource limited setting.  
As such, the main objective of this work was to develop and optimize a simple µPAD 
test for a capture assay using a custom made affibody molecule connected to a CBM (ZZapo-
CBM64) that could bind to the paper matrix of the µPAD and capture a target of interest, in 
this case Apo-A1 was used as a model, and successfully achieve detection using AuNPs 
conjugated with an Anti-Apo-A1 antibody.  
In this work, ZZapo-CBM64 was successfully produced and purified. To investigate 
if the purified ZZapo-CBM64 had the correct sequence, purified plasmid DNA was 
sequenced and compared with the original ZZapo-CBM64 sequence, which did not yield any 
mismatches, thus, the plasmid was correctly produced. Several tests were done to compare 
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it with ZZ-CBM64, a similar construct used to capture IgG rather than just Apo-A1. Both 
presented similar binding properties to cellulose, provided by the CBM64 part of the 
construct, successfully binding to cellulose particles and chromatography paper in a solution. 
Furthermore, capture capacity of IgG was assessed using IgG labelled with FITC for 
fluorescent analysis. ZZ-CBM64 captured IgG labelled to FITC successfully while the new 
ZZapo-CBM64 did not.  
A µPAD test was successfully designed and optimized for sample flow and reagent 
spotting using the AutoCad program. The use of an adhesive membrane on the bottom of the 
test strips also encouraged a faster elution of the sample and allowed the test to be run on a 
flat surface, as opposed to suspended.   
Anti-Apo-A1 conjugated and unconjugated AuNPs were ran through paper tests 
which got stuck in the initial part of the channel, but by adding Tween20 to the running 
buffer this problem was no longer observable.  ZZapo-CBM64 showed a false positive signal 
when Apo-A1 was not present, due to unspecific binding, which was solved by adding BSA 
to the running buffer and washing the channels with the same buffer before adding the 
sample. Additionally, this membrane did not show any other effects with Anti-Apo-A1 
conjugated and unconjugated AuNPs.  If the sample contained Apo-A1 the adhesive 
membrane had some interaction with it, causing the sample to not flow through the test, but 
by using a NH4HCO3 buffer instead of PBS, this problem was solved.  
Detection of Apo-A1 in the µPAD tests was not achieved. Native-PAGE and a 
cellulose binding test were conducted to ascertain the cause of the failed capture. Results 
indicated that ZZapo-CBM64 was not capturing Apo-A1, being the cause for not having a 
successful detection.  
Future works could include the study of the 3D structure of ZZapo-CBM64, in order 
to understand if it has any influence in the capture zone and if it could be the reason Apo-
A1 is not being captured. Furthermore, other affibody variants could be studied to understand 
if the problem observed is a common factor in constructs such as the one presented in this 
work or not. Once this is accomplished, optimization of the detection system should be made, 
working with detection limits to develop a test that if positive or negative detects an anomaly 
in the test subjects’ organism (i.e. low Apo-A1 levels could indicate chronic liver or kidney 
disease, if the tests’ detection range is at normal levels, a negative result could mean an 
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anomaly). The following steps could be testing in actual blood samples for validation of the 
method. 
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APPENDIX A: MAP OF THE FINAL PET21A VECTOR 
 
 
Figure 29 – Plasmid map of the final vector of pET21a containing the ZZapo-CBM64 module and restriction enzymes 
marked on the vector. 
